# From menarche to menopause: the impact of reproductive factors on the metabolic profile of over 65,000 women

- 3
- 4 Gemma L Clayton<sup>1,2\*</sup>, Maria Carolina Borges<sup>1,2\*</sup>, Deborah A Lawlor<sup>1,2,3</sup>
- 5 \*Joint first authors
- 6 <sup>1</sup> MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK.
- <sup>2</sup> Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
- 8 <sup>3</sup> NIHR Bristol Biomedical Research Centre, Bristol, UK.
- 9

# 10 Corresponding Author

- 11 gemma.clayton@bristol.ac.uk
- 12 University of Bristol,
- 13 Oakfield House, Dr Gemma L Clayton
- 14
- 15 Oakfield Road,
- 16 Bristol,
- 17 BS8 2BN
- 18
- 19 Word count:
- 20 **Figures:** 4
- 21 Tables: 1
- 22

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

# 23 Abstract (155)

24

25 We explored the relation between age at menarche, parity and age at natural menopause with 26 249 metabolic traits, measured using nuclear magnetic resonance (NMR), in up to 65,487 UK 27 Biobank women using multivariable regression (MV), Mendelian randomization (MR) and a 28 male negative control (parity only). Older age of menarche was related to a less atherogenic 29 metabolic profile in MV and MR, which was largely attenuated when accounting for adult body mass index. In MV, higher parity related to complex changes in lipoprotein-related traits; these 30 were not observed in male negative controls and were imprecisely estimated in MR. In MV 31 and MR, older age at natural menopause was related to lower concentrations of inflammation 32 markers, but inconsistent results were observed for LDL-related traits due to chronological 33 age-specific effects. Our findings support a role of reproductive traits on later life metabolic 34 profile and provide insights into identifying novel markers for the prevention of adverse 35 cardiometabolic outcomes in women. 36

37

#### 38 Introduction

#### 39

Markers of women's reproductive health, such as age at menarche, parity and age at 40 menopause, have been associated with several common chronic conditions, including 41 cardiometabolic diseases <sup>1-6</sup> and breast, ovarian and endometrial cancer <sup>7-12</sup>. Some attempts 42 have been made to explore the extent to which these associations are causal, as opposed to 43 explained by residual confounding, using approaches such as Mendelian randomization (MR) 44 and negative control designs, which are less prone to bias by key confounders from 45 conventional observational studies. MR studies suggest a direct positive effect of age at 46 menarche on breast cancer and an indirect inverse effect via body mass index (BMI)<sup>13</sup>, as 47 well as a possible bidirectional relationship between age at menarche and BMI <sup>13,14</sup>. MR also 48 supports a protective effect of older age at first birth on type 2 diabetes and cardiovascular 49 diseases <sup>15</sup> and lower mean levels of BMI, fasting insulin and triglycerides in women and men 50 <sup>16</sup>, while a partner negative control study provides some evidence of a 'J-shaped' effect of 51 52 parity on coronary heart disease risk <sup>5</sup>. In addition, evidence from MR studies indicate that 53 older age at menopause increases the risk of breast, endometrial and ovarian cancer, reduces 54 the risk of bone fractures and type 2 diabetes, and do not substantially affect BMI or cardiovascular diseases risk <sup>17</sup>. 55

Metabolites could act as mediators of the relationship of reproductive markers, and 56 related hormonal changes, with chronic diseases <sup>18-20</sup>. Determining the effect of women's 57 reproductive markers on multiple metabolites would be the first step to exploring this and could 58 provide crucial insights into mechanisms underlying women's long-term health. We have 59 previously shown marked changes in metabolites, such as lipids, fatty acids, amino acids and 60 inflammatory markers during pregnancy <sup>20</sup>, through the menopausal transition <sup>21</sup>, and among 61 women on hormonal contraceptives containing estrogen <sup>22</sup>. Many of these same metabolic 62 measures are also related to cardiovascular diseases <sup>19</sup> and some cancers <sup>23-26</sup>. The aim of 63 this paper is to explore the extent to which women's reproductive markers have a causal effect 64 on 249 metabolic measures (covering lipids, fatty acids, amino acids, glycolysis, ketone bodies 65 66 and an inflammatory marker). We focus on three reproductive traits that represent key events 67 in women's reproductive lives: (i) age at menarche, a marker of puberty timing, (ii) parity, a marker of repeated exposure to the physiological challenges of pregnancy, and (iii) age at 68 69 menopause, a marker of reproductive aging. We explore the causal relationships between reproductive markers and metabolic measures by triangulating evidence <sup>27</sup> across 70 multivariable regression, a negative control design (for parity only), and MR (Figure 1). Given 71 each of these approaches has unique strengths and limitations, results that agree across them 72 are less likely to be spurious <sup>27</sup>. 73

#### 74 **Results**

We used data from 65,699 UK Biobank female participants with 249 metabolic 75 76 measures quantified by nuclear magnetic resonance (NMR). Self-reported age at menarche 77 (in years), parity (in number of live born children) and age at menopause (in years) were reported at baseline when participants mean age was 56 years old (range: 37 to 73). NMR 78 metabolites were measured on blood samples taken at baseline or first repeat assessment 79 (more details in methods). The characteristics of these participants are shown in **Table 1** (and 80 split by each of our reproductive markers (categorized) in Supplementary Tables 1-3). At 81 recruitment (baseline) women were aged (mean) 56 (SD=8.0) years, 21% drank three or four 82 times a week and 40% were previous/currents smokers. 81% of women had one or more live 83 84 births whilst the mean age of menarche was 13 years (SD=1.3). 59% (37, 428) women reported they went through a natural menopause with a mean age of menopause of 49.7 years 85 (SD=5.1). Supplementary Table 4 shows the distribution of NMR metabolic measures among 86 87 UK Biobank females. The proportion of women with missing data across metabolic measures ranged from 0.3% to 6.1%. 88

89 We used three approaches relying on different assumptions to explore the causal role 90 of women's reproductive markers on later life metabolic profile. For the first approach 91 ('multivariable regression'), we used linear regression models to estimate the association of 92 reproductive markers with metabolic measures after adjusting for age at baseline, education and body composition at age 10. In sensitivity analyses, for the 55 non-derived metabolites, 93 we categorised age at menarche, parity and age at natural menopause, tested for a linear 94 95 trend and, where there was evidence of non-linearity, fit restricted cubic splines. For the 96 second approach ('negative control design' - only applicable for parity), we used linear regression models to test whether number of live born children in men was associated with 97 their metabolic measures; given men do not experience the repeated physiological stress of 98 pregnancy, but are likely to demonstrate the same associations of confounders (eg. 99 socioeconomic position, BMI, smoking) with number of live births, similar associations of 100 101 number of live births with metabolic measures between men and women would indicate bias 102 (e.g. due to confounding) rather than a causal effect of being exposed to the physiological stress of pregnancy on women's metabolic profile. For the third approach ('MR'), we selected 103 single nucleotide polymorphisms (SNPs) as genetic instruments for each reproductive marker 104 105 from previous genome-wide association studies (GWAS) and performed two-sample MR to 106 estimate the effect of reproductive markers on metabolic measures using the standard inverse 107 variance weighted (IVW) method. For both multivariable and MR analyses, we adopted P-108 value < 0.00093, which accounts for the approximate number of independent tests as detailed 109 in 'Statistical analyses'.

110

#### 111 Age at menarche

112

In the main multivariable regression analyses (adjusting for age at baseline, education and 113 114 body composition at age 10), older age at menarche was associated with higher concentration of glutamine, glycine, albumin, apolipoprotein A1, cholines, phosphatidylcholines, and 115 116 sphingomyelins but lower concentration of alanine, branched-chain amino acids (isoleucine, 117 leucine and valine), aromatic amino acids (phenylalanine and tyrosine), fatty acids (monounsaturated fatty acids (MUFA), omega-3 polyunsaturated fatty acids (PUFA), and 118 saturated fatty acids (SFA)), glycolysis-related metabolites (glucose, lactate, pyruvate), 119 120 acetoacetate, and glycoprotein acetyls (GlycA) (P < 0.00093) (Figure 2A and Supplementary 121 
 Table 5). Older age at menarche was also associated with numerous lipoprotein-related traits
 122 at P < 0.00093, particularly with higher number of particles, size, and lipid content in high-123 density lipoproteins (HDL) and lower number of particles, size, and lipid content in very lowdensity lipoproteins (VLDL) (Figure 2A). The associations of age at menarche with HDL-124 related traits were mostly due to larger HDL subclasses (i.e. medium, large and very large 125 particles), while associations with VLDL-related traits were observed across VLDL subclasses 126 127 (Supplementary Figure 1 and Supplementary Table 5). In sensitivity analyses with further adjustments for BMI, smoking and alcohol status at baseline, findings for an association of 128 older age at menarche were largely or completely attenuated towards the null for most 129 metabolic measures with few exceptions, such as glutamine, glycine, omega-3 PUFA, 130 131 pyruvate, lactate, and acetoacetate (Supplementary Figure 2). There was evidence of nonlinearity between categories of age at menarche (<13, 13-14, >14 years) and 17 metabolites 132 133 (Supplementary Table 6 and Supplementary Figure 3). Restricted cubic spline models (with 134 3 knots at ages 11, 13, and 15 years) generally showed an increase in albumin, apolipoprotein 135 A1, cholines, DHA, LA, and phosphatidylcholines with older age at menarche until 136 approximately age 13, in line with our linear association, and then began to flatten and/or decrease (Supplementary Table 7 and Supplementary Figure 4). Whilst older age at 137 138 menarche was related to an increase in GlycA until ~13 years and then began to flatten.

For the MR analyses, we selected 389 SNPs as instruments for age at menarche, 139 which explained 7.4% of its phenotypic variance with a corresponding mean F statistic of 63 140 (Supplementary Table 8). Overall, MR estimates using IVW were in agreement with 141 multivariable regression estimates in direction and magnitude (Figures 2A and 142 Supplementary Figure 1); however, due to the higher degree of uncertainty for IVW 143 estimates, no result passed our threshold for multiple testing correction (P < 0.00093). 144 Following reviewer's comments, we repeated the IVW analyses for a larger sample of women 145 146 (N=216,514-241,244) for the eight biomarkers assayed using clinical chemistry techniques

147 that matched measures in the NMR metabolomics platform — i.e. albumin, apolipoprotein A1, 148 apolipoprotein B, glucose, HDL-cholesterol, LDL-cholesterol, total cholesterol, and 149 triglycerides. These results provided further evidence of older age at menarche being related to higher albumin, apolipoprotein A1, HDL-cholesterol, and lower triglycerides (P < 0.00093) 150 151 (Figure 3). Given the a priori evidence of bidirectional effects between age at menarche and 152 BMI, we also performed multivariable IVW accounting for adult BMI to estimate the direct effects of age at menarche on metabolic measures, which resulted in estimates partly or 153 completely attenuated to the null for most metabolic measures with few exceptions, such as 154 glutamine and glycine (Supplementary Figure 5 and 6). 155

- 156
- 157 Parity

158

In the main multivariable regression analyses (adjusting for age at baseline, education 159 160 and body composition at age 10), higher parity was related to higher concentrations of glycine 161 and leucine, but lower concentrations of histidine, fatty acids (docosahexaenoic acid (DHA), 162 Omega 3, Omega 6 PUFA), pyruvate, ketone bodies (acetate, acetoacetate, acetone and  $\beta$ -163 hydroxybutyrate), and apolipoprotein A1 (P < 0.00093) (Figures 2B and Supplementary Table 9). Higher parity was also associated with numerous lipoprotein-related measures at P 164 < 0.00093, particularly with lower and higher number of particles, size, and lipid content for 165 HDL and VLDL, respectively, as well as lower size of LDL particles (Figure 2B). The 166 167 associations of parity with lipoprotein-related measures were observed across most VLDL and HDL subclasses, whereas associations with LDL-related measures were mostly driven by 168 larger LDL particles (Supplementary Figure 7 and Supplementary Table 9). In sensitivity 169 analyses with further adjustments for BMI, smoking and alcohol status at baseline, higher 170 parity associations were consistent for glycine, histidine, fatty acids, pyruvate, ketone bodies, 171 apolipoprotein A1, and partly attenuated towards the null for VLDL- and HDL-related traits 172 (Supplementary Figure 8). There was some evidence of non-linearity between parity 173 (0,1,2,3+) and 28 metabolites (Supplementary Table 6 and Supplementary Figure 9). 174 However, restricted cubic spline models (with knots at 1, 2, and 3) generally showed 175 176 monotonic relationships for those with no to four pregnancies, consistent with the main 177 analysis models (Supplementary Table 10 and Supplementary Figure 10).

We used males as a negative control since men cannot experience the effects of being exposed to the stress test of pregnancy. Therefore, similar results between men and women would be indicative of bias, such as due to confounding by sociodemographic (e.g. education attainment) and biological (e.g. infertility) factors, rather than by an effect of repeated exposure to pregnancy. When using number of children in males as a negative control, we observed that associations for leucine, histidine, pyruvate, and ketone bodies were similar between men

184 and women (i.e. directionally consistent, similar effect estimates and 95% confidence intervals 185 overlapped between male and female estimates). On the other hand, association estimates for fatty acids, apolipoprotein A1, and lipoprotein-related traits were weaker or consistent with 186 the null, and glycine was in opposite direction, in males compared to females (Figure 4). For 187 188 the MR analyses, we selected 32 SNPs as instruments for parity, which explained 0.2% of its 189 phenotypic variance with a corresponding mean F statistic of 31 (Supplementary Table 8). It is unclear whether estimates from multivariable regression and MR analyses are consistent 190 191 with each other due to the high level of uncertainty in the latter (Figures 2B and 192 **Supplementary Figure 7**), which persisted even when using the larger sample of women with selected biomarkers assayed by clinical chemistry (Figure 3). 193

194

# 195 Age at natural menopause

196

In the main multivariable regression analyses (adjusting for age at baseline, education 197 198 and body composition at age 10), older age at menopause was related to higher glycine, PUFA 199 (e.g. DHA and LA), albumin, apolipoprotein B and sphingomyelins, but lower concentration of 200 MUFA, pyruvate, acetoacetate, creatinine and GlycA (P < 0.00093) (Figures 2C and **Supplementary Table 11**). Older age at menopause was also associated with numerous 201 lipoprotein-related traits at P < 0.00093, particularly with higher number of particles and lipid 202 content in LDL, larger size of HDL particles, and lower size of VLDL particles (Figure 2C). The 203 204 associations between age at menopause and LDL-related traits were observed across LDL subclasses (i.e. from small to large), whereas associations with HDL-related traits were mostly 205 driven by larger HDL particles (Supplementary Figure 11). In sensitivity analyses with further 206 adjustments for BMI, smoking and alcohol status at baseline, associations between older age 207 at natural menopause and metabolites remained similar, except for associations with HDL-208 related traits which were partly attenuated (Supplementary Figure 12). There was evidence 209 of non-linearity across 24 metabolites (Supplementary Table 6 and Supplementary Figure 210 211 **13**) in the multivariable regression when menopause was categorised (<49, 49-50, 51-53, >53) years). Restricted cubic spline models (with 4 knots) were generally consistent with the main 212 213 analysis (assuming a linear association) until age at menopause ~55 years when most 214 metabolites decreased (Supplementary Table 12 and Supplementary Figure 14).

For the MR analyses, we selected 290 SNPs as instruments for age at natural menopause, which explained 8.2% of its phenotypic variance with a corresponding mean F statistic of 141 (**Supplementary Table 8**). Estimates from multivariable regression and MR analyses were inconsistent in direction for many metabolic measures (**Figure 2C**). In particular, in contrast to results from multivariable regression, MR analyses indicated older age at menopause to be related to lower concentration of fatty acids (e.g. LA), albumin,

221 apolipoprotein B, as well as lower number of particles, lipid content and size of LDL across 222 subtypes (from small to large) (Figure 2C and Supplementary Figure 11). For some 223 metabolites, such as GlycA and HDL-related traits, results were consistent in direction between multivariable regression and MR. For alanine, glutamine and glucose, MR analysis 224 225 suggested older age of menopause to be related to lower circulating metabolite levels, which 226 had not been observed in multivariable regression analysis (Figures 2C and Supplementary Table 11). As expected, there was more uncertainty in MR estimates and only results for 227 228 glutamine and some LDL- and VLDL-related measures passed the threshold for multiple test 229 correction (P < 0.00093). Repeating the MR analyses in the larger sample of women (N=216,514-241,244) with selected biomarkers assayed by clinical chemistry confirmed that 230 older age at natural menopause was related to lower albumin, LDL-cholesterol, and total 231 cholesterol at P < 0.00093 (Figure 3). 232

We performed further analyses to investigate reasons underlying discrepant findings 233 234 between multivariable and MR estimates for some metabolic measures. These analyses were restricted to the eight clinical chemistry biomarkers matching measures in the NMR platform 235 236 to maximise statistical power since they have been measured in the full UK Biobank sample. 237 First, we hypothesised that discrepant findings were related to differences in the sample used 238 for multivariable regression, which excludes women with missing data on age at menopause (hereafter 'selected sample'), and two-sample MR, which includes women even if they are 239 240 missing data on age at natural menopause (hereafter 'full sample'). To test that, we compared 241 estimates from multivariable regression on the selected sample to MR on both the selected 242 sample and full sample. In agreement with our hypothesis, multivariable regression and MR 243 estimates for LDL-cholesterol and related traits (i.e. apolipoprotein B and total cholesterol) are 244 comparable when restricting to the selected sample. In contrast, for albumin, discrepant 245 results were related to differences between multivariable regression and MR rather than between selected and full sample (Supplementary Figure 15). Second, given women with 246 247 missing data at age at menopause are typically pre-menopausal and younger, we explored age-stratified multivariable and MR estimates, which revealed a strong effect modification by 248 chronological age on the association of age at menopause with LDL-c and related traits – e.g. 249 older age at menopause is related to substantially lower LDL-cholesterol in younger women 250 251  $(\leq 50 \text{ y})$  (e.g. MV: -0.018 SD, 95%CI: -0.021, -0.015), but slightly higher LDL-cholesterol in 252 older women (> 63 y) (e.g. MV: 0.004 SD, 95%CI: 0.003, 0.006) (Supplementary Figure 15). 253 Differences related to chronological age at baseline were also observed for other biomarkers, such as albumin. This age patterned results were largely similar when excluding women using 254 255 statins at baseline or with a history of using hormone replacement therapy (HRT) 256 (Supplementary Figure 16).

#### 257

# 258 Exploring the plausibility of MR assumptions

259

We conducted a series of sensitivity analyses to explore the plausibility of key MR assumptions, required for the method to provide a valid test of the presence of a causal effect.

First, we tested whether MR findings are likely to be biased by population stratification, 262 assortative mating and indirect genetic effects of parents using two approaches: (i) performing 263 two-sample MR analyses using (sex-combined) data from a recent within-siblings GWAS, and 264 265 (ii) conducting two-sample MR on negative control outcomes (i.e. skin colour and skin tanning ability). Two-sample MR estimates for the effect of genetic susceptibility for older age at 266 menarche, parity, and age at natural menopause on five available biomarkers was broadly 267 consistent when estimated among unrelated individuals or between siblings. Results for age 268 at menarche were slightly overestimated for triglycerides and underestimated for glycated 269 270 haemoglobin in unrelated individuals, while results for a positive relation between age at natural menopause and HDL-cholesterol was supported by analyses between siblings but not 271 among unrelated individuals (Supplementary Figure 17). We did not observe an association 272 of genetically-predicted reproductive markers with skin colour or tanning (Supplementary 273 274 **Table 13**). Taken together, these sensitivity analyses indicate that our main MR estimates are 275 unlikely to be substantially biased by population stratification, assortative mating and indirect 276 genetic effects of parents.

277 Second, we explored the presence of bias due to pleiotropic variants by using MR 278 methods other than IVW: the weighted median estimator and MR-Egger. These methods can 279 provide valid tests for the presence of a causal effect under different (and weaker) 280 assumptions about the nature of the underlying horizontal pleiotropy compared to IVW. 281 Estimates from IVW and weighted median were consistent in direction for most relationships 282 between reproductive markers and metabolic measures. In most instances, estimates from MR-Egger method were uninformative given the high degree of uncertainty (**Supplementary** 283 284 Figures 18, 19, 20).

Third, we assessed potential bias due to sample overlap from including UK Biobank individuals in genetic association estimates for both exposures and outcomes. This was achieved by using data from previous GWAS that did not include UK Biobank, available for age at menarche and age at natural menopause, to select SNPs (and genetic associations estimates with exposures) for two-sample MR analyses (**Supplementary Table 14**). When using SNPs selected from previous GWASes that did not include UK Biobank participants, results for of age at menarche and age at natural menopause were largely consistent, although

less precise, compared to estimates from the main analyses using data with overlapping
samples (Supplementary Figure 21 and 22).

294

#### 295 Discussion

296

Our findings indicate that reproductive markers across women's lifespan are associated with distinct metabolic signatures in later life. Age at menarche, parity and age at natural menopause were related to numerous metabolic measures, representing multiple dimensions of metabolism, including amino acids, fatty acids, glucose, ketone bodies, and lipoprotein metabolism (see **Summary box** for key findings).

#### 302 Age at menarche

Age at menarche is frequently used as a proxy of puberty onset among females in epidemiological studies <sup>2,28</sup>. Our findings for the relation of age at menarche with metabolic measures were broadly concordant between multivariable regression and MR analyses, and were supportive of older puberty onset being related to a less atherogenic metabolic profile among adult women.

Both multivariable regression and MR estimates were markedly attenuated when accounting for adult BMI for most metabolic measures with few exceptions (e.g. glutamine and glycine), suggesting that the effect of age at menarche on adult metabolites are largely explained by adult BMI. There is evidence of a bi-directional relationship between puberty timing and adiposity, where pre-pubertal adiposity influences puberty timing, which in turn influences post-pubertal adiposity <sup>13,28,29</sup>. In addition, genetic variants influencing age at menarche are known to influence BMI before and after puberty <sup>28,29</sup>.

The complex relationship between puberty timing and adiposity complicates inferences 315 of the effect of age at menarche on the metabolic profile or disease risk in adulthood since the 316 317 observed associations could reflect adult BMI mediating the effect of early age at menarche on metabolic measures or a confounding path from pre-puberty BMI. A previous one-sample 318 MR study <sup>28</sup> investigating the effect of age at menarche on NMR metabolic measures reported 319 that results were largely attenuated when accounting for BMI at 8 years old, which suggests 320 that the estimated effect of age at menarche on the metabolic profile is largely confounded by 321 322 pre-pubertal adiposity, though larger MR studies with repeat BMI and metabolic profiles before 323 and after menarche are needed to rule out a potential causal mediated effect. In our study, accounting for self-reported adiposity in childhood in multivariable regression models did not 324 325 substantially change effect estimates. This discrepancy might be related to residual

confounding in our study (e.g. due to higher measurement error in our measure of childhood
 adiposity) or different age distributions between ours (mean=55 years) and this previous study
 (mean=18 years).

329 Parity

Pregnant women undergo marked changes in physiology (e.g. lipid/glucose 330 metabolism, adiposity, vascular function, hormone levels, and inflammatory response) and 331 lifestyle (e.g. diet and physical activity <sup>30</sup>), most of which return to their pre-pregnancy state 332 after delivery <sup>20,30</sup>. However, there are concerns that some of these changes might persist and 333 accumulate over multiple pregnancies, impacting women's cardiovascular health in the future, 334 or that pregnancy acts as a stress test, unmasking an underlying high risk for cardiovascular 335 disease <sup>30,31</sup>. We used parity as a marker of being exposed to the physiological stress of 336 337 multiple pregnancies.

In multivariable regression analyses, we found that higher parity, proxied by number of 338 children ever born, was associated with both favorable (e.g. less LDL particles) and 339 unfavorable (e.g. higher number of particles and lipid content in VLDL) changes in the 340 341 metabolic profile. Evidence from MR analyses is uncertain due to the high imprecision in effect estimates. Using males as a negative control, we showed that the associations between 342 number of children ever born and metabolic measures among men were largely null for 343 lipoprotein-related measures or in opposite direction for glycine compared to females. This 344 345 inconsistency between female and male findings reinforces that the metabolic signature associated with parity among females largely reflects a causal effect of parity on the 346 metabolome rather than spurious results due to confounding or selection bias (assuming 347 confounding structures and selection mechanisms are similar between men and women). A 348 349 possible mechanism is that higher parity leads to greater insulin resistance in pregnant women 350 and subsequently increases the production and secretion of hepatic triglycerides, which can 351 lead to an increased lipid content in VLDL particles.

In line with our findings, other studies have reported that higher parity is related to 352 higher cardiovascular disease risk in women <sup>32</sup>. Negative control analyses (comparing 353 associations of number of children in women and men) have been conducted previously in 354 355 two UK cohorts, with one suggesting that associations with lipids and body composition in women may be due to confounding (as associations are similar in women and men) <sup>33,34</sup> and 356 357 the second, the largest of these studies to date, and the only one to look at disease end points, 358 finding evidence of a stronger association for risk factors and coronary heart disease in women 359 than men suggesting parity itself has some influence on cardiovascular disease risk <sup>5</sup>,

Furthermore, studies in women only that are able to control for pre-pregnancy measures, suggest pregnancy and parity have a potentially lasting effect on adverse lipid profiles <sup>35,36</sup>.

#### 362 Age at natural menopause

Previous conventional observational studies suggested older age at natural 363 menopause to be associated with lower risk of cardiometabolic diseases <sup>37</sup> over and above 364 the underlying age trajectory <sup>21,38</sup>. In our study, estimates for VLDL- and LDL-related traits 365 were inconsistent between multivariable regressions and MR; the former suggests older age 366 367 at menopause to be related to a more atherogenic profile, while the latter indicates the opposite. On the other hand, both multivariable regression and MR estimates suggested older 368 age at menopause to be related to higher lipid content in HDL particles and lower systemic 369 inflammation, as proxied by GlycA. Consistent with Auro et al <sup>39</sup>, a recent multivariable 370 371 analysis of 218 Finnish women going through the menopause transition found that menopause 372 was similarly associated with a higher lipid content in HDL particles and lower systemic 373 inflammation <sup>40</sup>. Whilst a recent longitudinal study of up to 3892 women with up to 12 CVD risk 374 factors measured as they went through the menopausal transitional also found higher HDL and non-HDL associations, stronger effects of chronological rather than reproductive aging 375 376 were observed <sup>41</sup>.

Findings from our multivariable regression analyses for age at natural menopause 377 should be interpreted with caution given 40% of women were excluded from these analyses 378 379 as they had not experienced a natural menopause and 7% of the women had experienced 380 menopause less than two years before study recruitment (when blood samples for NMR metabolomics were collected). In follow-up analyses, we have shown that discrepancy in 381 findings between multivariable and MR for LDL-related traits were related to the exclusion of 382 383 younger pre-menopausal women in multivariable regression. In addition, age-stratified 384 analyses revealed that age at menopause is related to lower LDL-cholesterol in younger women but slightly higher LDL-cholesterol in older women. These results did not seem to be 385 explained by higher intake of statins or HRT among older women, although such analyses 386 387 should be interpreted with caution given the potential for collider stratification bias. Previous longitudinal studies indicated that LDL-cholesterol<sup>41</sup> and related traits increase sharply 388 through the menopause transition and early postmenopausal years and then plateau with 389 390 increasing postmenopausal years <sup>42</sup>. In our cross-sectional analyses, we observed a non-391 linear pattern for several metabolites, such that mean metabolite levels increase linearly with age at menopause until 50-55 years old and then decline. Taken together, we speculate that 392 these findings explain the pattern by chronological age in the association between timing of 393 394 menopause and LDL-related traits. However, larger longitudinal studies with longer follow-up are needed to tease apart the complex nature, and possible time-varying, effect ofreproductive aging on the metabolome.

The largest two-sample MR analysis to date indicate that older age at menopause is 397 related to lower risk of type 2 diabetes in females, but no difference in risk of cardiovascular 398 disease or dyslipidemia (data combining males and females)<sup>43</sup>. This is in agreement with our 399 analyses suggesting older age at natural menopause is related to lower glucose, and with 400 401 evidence from randomized controlled trials of estrogen therapy pointing to a protective effect on type 2 diabetes but no change in risk of cardiovascular diseases <sup>44-46</sup>. The mechanisms 402 underlying the putative protective effect of older menopause on the risk of metabolic diseases 403 in MR studies is unclear, but might reflect an effect of prolonged exposure to sex hormones 404 405 or of slower cell aging, given genetic variants associated with age at natural menopause are highly enriched for genes in DNA damage response pathways <sup>43,47</sup>. The consistent results 406 between MR of age at menopause and randomized controlled trials of estrogen therapy for 407 408 type 2 diabetes indicates that prolonged exposure to sex hormones is likely to be involved. 409 Moreover, the lipid metabolism is regulated by estrogen, meaning that lower levels of estrogen 410 during menopause can cause an increase in lipids, particularly LDL, HDL, and triglycerides.

#### 411 Strengths and limitations

To the best of our knowledge, this is the largest study to examine the long-term impact of key events in reproductive life on the multiple metabolic measures in women. The use of large-scale metabolomics data and the integration of multiple analytical approaches are key strengths of our study as these allowed us to strengthen the inference of the causal impact of these reproductive markers on the metabolic health of females.

417 It is important to note that the validity of our findings rely on the plausibility of the 418 assumptions underlying each analytical approach. For multivariable regression, we cannot 419 exclude the possibility of bias due to residual confounding, especially given we were unable 420 to adjust for key confounders in multivariable regression as measures of these were not available at or before the exposure to reproductive factors. For the use of negative controls, 421 we rely on the unverifiable assumption that residual confounding and selection bias is similar 422 in females and males analyses. It is plausible that factors relating to metabolites, such as age, 423 424 ethnicity, socioeconomic position, and BMI, relate similarly to number of children in females and males and hence that confounding structures are similar. For MR, we have conducted 425 426 extensive sensitivity analyses supporting the validity of our results; however, we cannot rule 427 out the possibility of bias due to violations of the core instrumental variable assumptions. In addition, MR analyses for parity was uninformative given the low proportion of phenotypic 428 variance explained by the genetic instruments. 429

430 When assessing non-linearity, our multivariable regression results were generally 431 consistent between the main analysis model (assuming a linear relationship) and categories 432 for most metabolites. For metabolites that showed evidence of non-linearity, many seemed to plateau and decrease with older ages of menarche and menopause and similarly with higher 433 434 parity (however, this was also where we had the least amount of data, which could be driving some of the non-linearity). We were unable to fit non-linear associations in an MR framework 435 given this would require much larger sample sizes; future studies with larger sample sizes 436 should be better powered to examine potential non-linear effects using MR and contrast those 437 found in the multivariable regression. 438

Whilst some key sources of bias may remain in each method, a key strength of our study is exploring and focusing on results that are consistent across the different methods. As the sources of bias differ between the methods causal inference is strengthened where there is consistency, as we see for example in associations between multivariable regression and MR for age at menarche, multivariable regression and negative control analyses for parity and multivariable regression and MR for age at natural menopause in relation to HDL-related measures and GlycA (but not LDL-related and other measures).

446 Across all analytical approaches, we cannot discard the presence of selection biases from using UK Biobank data given the low recruitment rate of the study (5%) and inclusion of 447 healthier/wealthier individuals compared to the general UK population <sup>48</sup>. In addition, the 448 metabolic traits measured by the NMR metabolomics platform cover a limited set of metabolic 449 pathways<sup>49</sup>, and, therefore, future studies including data from more sensitive metabolomics 450 techniques, such as mass spectrometry, may improve coverage of the metabolome and 451 provide insights into additional biological processes related to reproductive events. 452 Triangulating results across different methods is useful for causal inference and where there 453 are discrepant results it is important to explore these. We have found that the discrepant 454 455 results between MR and multivariable regression for the association of age at menopause with some of the metabolites (notably LDL-c and related metabolites) are due to the exclusion of 456 women with missing data on age at menopause in multivariable regression and a potential 457 458 effect modification by chronological age in the association between age at menopause and 459 some metabolic measures. However, we acknowledge we lack power to fully explore the 460 mechanisms for this given the current number of UK Biobank participants with NMR data.

461

# 462 Conclusions

463 Overall, older age at menarche/menopause were related to a more favorable metabolic 464 profile, while a mixed pattern was observed for higher parity. Evidence supporting a relation

between later pubertal timing and a less atherogenic metabolic profile was largely explained by adult BMI, while findings supporting a relation between slower reproductive aging and a less atherogenic metabolic profile was mostly observed among younger women. These results could contribute to identifying novel markers for the prevention of adverse cardiometabolic outcomes in women and/or methods for accurate risk prediction.

470

#### 471 Methods

472

# 473 Study participants

UK Biobank is a population-based cohort consisting of approximately 500,000 men 474 and women recruited between 2006 and 2010 from across the UK (age range at recruitment: 475 38 years to 73 years old) <sup>50</sup>. UK Biobank participants have provided a range of information via 476 questionnaires and interviews, including on sociodemographic, lifestyle, health, and 477 reproductive factors; as well as biological samples and physical measures (data available at 478 www.ukbiobank.ac.uk). A subset of approximately 20,000 were selected for repeat 479 assessment between 2012 and 2013. A full description of the study design, participants and 480 guality control (QC) methods have been described in detail previously <sup>51</sup>. UK Biobank received 481 ethical approval from the Research Ethics Committee (REC reference for UK Biobank is 482 11/NW/0382). The current work was approved under UK Biobank Project 30418 and 81499. 483

484

# 485 *Reproductive traits*

Women were asked a detailed set of questions about their reproductive health via a 486 self-reported questionnaire. Parity was based on the number of live births reported whilst in 487 488 men number of children were reported. Age at menarche and age at natural menopause were reported in years. Age at natural menopause therefore excluded women who had not yet gone 489 through the menopause or who had a surgical menopause. Those who had not gone through 490 491 a natural menopause (N=25,70) had either (i) not yet gone through the menopause (15,418, 60%) (ii) had a surgical menopause or other (10,322, 40%) (Table 1, Supplementary Table 492 3). 493

494

# 495 NMR metabolic measures

Metabolic traits were measured using a targeted high-throughput NMR metabolomics
 (Nightingale Health Ltd; biomarker quantification version 2020)<sup>52</sup>. This platform provides
 simultaneous quantification of 249 metabolic measures, consisting of concentrations of 165

499 metabolic measures and 84 derived ratios, encompassing routine lipids, lipoprotein subclass 500 profiling (including lipid composition within 14 subclasses), fatty acid composition, and various 501 low-molecular weight metabolites such as amino acids, ketone bodies and glycolysis metabolites. Technical details and epidemiological applications have been previously 502 reviewed <sup>18,53</sup>. Pre-release data from a random subset of 126,846 non-fasting plasma samples 503 collected at baseline or first repeat assessment were made available to early access analysts. 504 505 121,577 samples were retained for analyses after removing duplicates and observations not 506 passing quality control (QC) (i.e. sample QC flag "Low protein", biomarker QC flag "Technical 507 error", or samples with insufficient material). All metabolic measures were standardised and normalised prior to analyses using rank-based inverse normal transformation. 508

509

#### 510 Clinical chemistry measures

511 We used data on the eight biomarkers assayed using clinical chemistry techniques, as previously described <sup>54</sup>, that matched measures in the NMR metabolomics platform — i.e. 512 513 albumin, apolipoprotein A1, apolipoprotein B, glucose, HDL-cholesterol, LDL-cholesterol, total cholesterol, and triglycerides. These measures are available in most UK Biobank participants 514 515 and were used in Mendelian randomization analyses, as described under 'Statistical analyses', to increase statistical power and check agreement with results from NMR metabolic 516 517 measures. All biomarkers were standardised and normalised prior to analyses using rankbased inverse normal transformation. 518

519

# 520 Summary data on genetic associations with metabolic measures

521 Genotype data was available for 488,377 UK Biobank participants, of which 49,979 522 were genotyped using the UK BiLEVE array and 438,398 using the UK Biobank axiom array. Pre-imputation QC, phasing and imputation are described elsewhere <sup>55</sup>. Genotype imputation 523 was performed using IMPUTE2 algorithms <sup>56</sup> to a reference set combining the UK10K 524 haplotype and HRC reference panels <sup>57</sup>. Post-imputation QC was performed as described in 525 the "UK Biobank Genetic Data: MRC-IEU Quality Control" documentation <sup>58</sup>. Genetic 526 association data for metabolic measures was generated using the MRC IEU UK Biobank 527 GWAS pipeline <sup>59</sup>. Briefly, we restricted the sample to individuals of 'European' ancestry as 528 defined by the largest cluster in an in-house k-means cluster analysis performed using the first 529 530 4 principal components provided by UK Biobank in the statistical software environment R (n=464,708). Genome-wide association analysis (GWAS) was conducted using linear mixed 531 model (LMM) association method as implemented in BOLT-LMM (v2.3)<sup>60</sup>. Population 532 structure was modelled using 143,006 directly genotyped SNPs (MAF > 0.01; genotyping rate 533

> 0.015; Hardy-Weinberg equilibrium p-value < 0.0001 and LD pruning to an r2 threshold of</li>
 0.1 using PLINKv2.00). Models were adjusted for genotyping array and fasting time and were
 restricted to the subsample of women.

537

#### 538 Covariables

For multivariable analyses, confounders were defined a priori based on them being 539 known or plausible causal factors for reproductive traits and cardiovascular risk via 540 541 higher/lower metabolites. A minimal set of adjustments were made in the main multivariable regression analyses as most confounders were not assessed prior to or around when the 542 543 reproductive traits occurred. Specifically, we adjusted for education as a categorical variable (University, A-levels, O levels (or equivalent) or other), age at baseline and retrospectively 544 545 reported body size at age 10 (average, thinner, plumper) in all regression analyses. In 546 additional analyses we also partially adjusted for the full set of defined confounders using baseline measurements (mostly after the occurrence of exposures) as correlates of the before 547 exposure measures (see below in statistical analyses). 548

549

#### 550 Statistical analyses

We used multiple approaches (i.e. multivariable regression, negative control and MR) relying on different assumptions to explore the causal role of reproductive traits on later life metabolic profile. All analysis was conducted using Stata16 (StataCorp, College Station, TX) or R 4.1.1 (R Foundation for Statistical Computing, Vienna, Austria) and results presented as differences in means for each metabolic trait in standard deviation (SD) units per 1 child difference for number of children and per 1 year difference for age at menarche and age at menopause, facilitating the comparison of results from different methods.

For both multivariable and MR analyses, we corrected for multiple testing using the Bonferroni method considering 3\*18=54 independent tests (*P*=0.05/54≈0.00093). This was based on the three exposures included in our analyses (i.e. age at menarche, parity, and age at natural menopause) and the 18 independent features explaining over 95% of variance in the highly correlated NMR metabolic measures in our dataset as estimated by principal component analysis <sup>61</sup>.

564

#### 565 (a) Multivariable regression

566 In the main analyses we used linear regression, with three sets of models: (1) no 567 adjustments, (2) adjusted for education, age at baseline and body composition at age 10 and

568 (3) model (2) additionally adjusted for baseline variables collected at the first assessment at 569 (mean) age 56 years (SD=8) including BMI, smoking and alcohol status. By adjusting for the 570 baseline variables at the first assessment we can either block the confounding path or create bias if these variables are mediators. If the results change between model (2) and (3) it is hard 571 572 to distinguish whether its correct adjustment for confounding or whether it is a mediated path. 573 Because of this we considered model (2) to be the best causal estimate and present models (1) and (3) in supplementary material. For age at menarche, education will have been 574 measured after the exposure. However, as it is influenced by parental education, income and 575 576 occupation (occurring before menarche) unlikely to be determined by age at menarche, we a priori considered a proxy of early life <sup>62</sup>. In sensitivity analyses we assessed whether there 577 was a non-linear relationship between each reproductive trait and 55 non-derived metabolites. 578 For ease of presentation, we excluded measures that were derived (eg ratios) or related to 579 lipoprotein subfractions as these are highly correlated with one or more of the 55 non-derived 580 metabolites. We compared the categorised reproductive trait entered into the model as a 581 categorical variable and as a continuous variable using a likelihood ratio test. Age at menarche 582 583 and age at menopause were categorised into tertiles (<13, 13-14, >14 years) and quartiles 584 (<49, 49-50, 51-53, >53 years), respectively. Parity was categorised as 0, 1, 2, and 3+. Results 585 were plotted against the first reference category and the p-value for linear trend reported. For 586 any metabolites that showed evidence of non-linearity, restricted cubic splines (with either 3, 4, or 5 knots placed at percentiles as suggested by Harrell<sup>63</sup> for each reproductive trait) were 587 fit and compared to the main analysis model (assuming a linear association) using AIC (BIC 588 589 and root mean square error also shown).

590

#### 591 (b) Negative control analyses

Negative control analyses aim to emulate a condition that cannot involve the 592 hypothesized causal mechanism but is likely to have similar sources of bias that may have 593 been present in the association of interest <sup>5,27</sup>. We used males as negative controls to assess 594 potential biases in the association between parity (proxied by number of live births) and 595 596 metabolic measures in women. If associations between number of live births and metabolic 597 measures in women reflect a causal effect of parity on women's metabolic health, one would 598 expect number of live births to be associated with metabolic measures in women but not in 599 men given men do not experience pregnancy. Similar to the multivariable regression analyses, 600 we test the association between number of children (men) and their measured metabolites and present three sets of models: (1) with no adjustments, (2) adjusted for education, age at 601 baseline and retrospectively self-reported body composition at age 10 and (3) model (2) 602

additionally adjusted for baseline variables collected at the first assessment at (mean) age 56
 years (SD=8) including BMI, smoking and alcohol status.

605

# 606 (c) Mendelian randomization

We used two-sample MR to explore the effect of older age at menarche, higher parity, and older age at natural menopause on women's metabolic profile. Publicly available GWAS summary data were used for SNP-reproductive traits associations (sample 1) and UK Biobank summary GWAS data for SNP-metabolite associations (sample 2). This approach does not require all participants to have data on both exposure and outcome, and, therefore, allows us to retain the largest possible sample sizes, meaning that power to detect a causal effect is increased <sup>64</sup>.

614

#### 615 Selection of genetic instruments

616

#### 617 Age at menarche

Genetic instruments were selected from a GWAS of age at menarche, which included 618 329,345 women of European ancestry (Supplementary Table 14) <sup>65</sup>. Linear regression 619 models were used to estimate the association between genetic variants and age at menarche 620 (in years) adjusting for age at study visit and study-specific covariables. For our analyses, we 621 selected the 389 independent SNPs reported by the GWAS to be strongly associated with age 622 at menarche (P-value  $< 5^{*}10^{-8}$ ) in the discovery metanalyses. Given the age at menarche 623 624 GWAS included UK Biobank participants (maximum estimated sample overlap: ~20%), we 625 have also selected an additional set of age at menarche-associated genetic variants (N = 68 SNPs) using data from a previous GWAS that did not including UK Biobank (details in 626 627 'Sensitivity analyses' below and Supplementary Table 14)<sup>66</sup>.

- 628
- 629 Parity

Genetic instruments were selected from a GWAS of number of children ever born , as a proxy of parity, which included 785,604 men and women of European ancestry from 45 studies (**Supplementary Table 14**) <sup>67</sup>. Number of children ever born was treated as a continuous measure and included both parous and nulliparous women. Linear regression models were used to estimate the association between genetic variants and number of children ever born adjusting for principal components of ancestry, birth year, its square and cubic, to control for non-linear birth cohort effects. Family-based studies controlled for family

structure or excluded relatives. The sex-combined metanalysis also included interactions of
birth year and its polynomials with sex. For our analyses, we used the 32 independent SNPs
reported by the GWAS to be strongly associated with number of children ever born (P-value
< 5\*10<sup>-8</sup>) in either the sex-combined (28 SNPs) or female-specific (4 SNPs) metanalyses and
summary association data from the female-specific metanalyses. The GWAS included UK
Biobank (maximum estimated sample overlap: 14%).

643

# 644 Age at natural menopause

Genetic instruments were selected from a GWAS of age at natural menopause 645 conducted in 201,323 women of European ancestry (**Supplementary Table 14**)<sup>17</sup>. Linear 646 regression models were used to estimate the association between genetic variants and age 647 at natural menopause (in years). For our analyses, we selected 290 SNPs reported by the 648 GWAS to be strongly associated with age at natural menopause (P-value < 5\*10<sup>-8</sup>). Where 649 available, we used association data from the sample combining discovery and replication 650 stages (N = 496,151). Given the age at menarche GWAS included UK Biobank participants 651 652 (maximum estimated sample overlap: 13% considering the GWAS combined discovery and 653 replication samples), we have also selected an additional set of age at natural menopause-654 associated genetic variants (N = 42 SNPs) using data from a previous GWAS that did not 655 include UK Biobank (details in 'Sensitivity analyses' below and Supplementary Table 14) 68. 656

#### 657 Main analyses

We used a standard two-sample MR method, the inverse variance weighted (IVW) 658 estimator, to explore the effect of age at menarche, parity and age at natural menopause on 659 660 women's metabolic profile by combining genetic association estimates for reproductive traits 661 (extracted from published GWASes data) with genetic association estimates for the metabolic 662 measures (generated from UK Biobank data). Given a priori evidence of a potential bidirectional relationship between age at menarche and BMI, we also used multivariable IVW 663 to test the effect of age at menarche on metabolic measures accounting for adult BMI. For 664 665 multivariable IVW analysis, apart from the data previously described, we used summary genetic association data for BMI extracted from the 2015 metanalysis by the GIANT 666 consortium (N = 339,224 individuals not including UK Biobank participants) <sup>69</sup>. 667

668

# 669 Sensitivity analyses

670 Several sensitivity analyses were conducted to explore the plausibility of the three core 671 MR assumptions, which are required for the method to provide a valid test of the presence of 672 a causal effect.

673

Assumption 1: the genetic instrument must be associated with the reproductive trait

675 We selected genetic variants reported to be strongly associated with reproductive in 676 the largest available GWAS and estimated the proportion of phenotypic variance explained 677 ( $R^2$ ) and F-statistics for the association of SNPs with reproductive traits among females as an 678 indicator of instrument strength.

679

680 Assumption 2: the association between genetic instrument and outcome is unconfounded

681 One of the main motivations for using MR is to avoid unmeasured confounding. However, there is growing evidence that, in some instances, MR studies can be confounded 682 when using data from unrelated individuals due to population stratification, assortative mating 683 and indirect genetic effects of parents <sup>70,71</sup>. We used two approaches to explore whether these 684 685 were likely to bias our main results. First, we used sex-combined data from a recent withinsibship GWAS, including up to 159,701 siblings from 17 cohorts, to test the effect of genetic 686 susceptibility to higher age at menarche, parity and age at menopause on metabolic markers 687 688 (i.e. LDL-cholesterol, triglycerides, HDL-cholesterol, C-reactive protein, and glycated 689 haemoglobin) <sup>70</sup>. C-reactive protein and glycated haemoglobin were used as proxies for 690 inflammation and hyperglycaemia, respectively, given GlycA and glucose were not available. 691 Within-sibling MR designs control for variation in parental genotypes, and so should not be affected by population stratification, assortative mating and indirect genetic effects of parents 692 <sup>70-72</sup>. Second, we performed IVW on negative control outcomes (i.e. skin colour and skin 693 694 tanning ability) since these could not conceivably be affected by the exposures and any evidence for an association between reproductive traits and, these negative control outcomes 695 would be indicative of residual population stratification in the exposure GWAS 73. 696

697

Assumption 3: the genetic instrument does not affect the outcome except through its possibleeffect on the exposure

700 A key violation of this assumption is known as horizontal pleiotropy, where genetic variants influence the outcome through pathways that are not mediated by the exposure <sup>74</sup>. 701 702 We explored the presence of bias due to horizontal pleiotropy by using other MR methods: 703 the weighted median estimator and MR-Egger. These methods can provide valid tests of a causal effect under different (and weaker) assumptions about the nature of the underlying 704 horizontal pleiotropy. The weighted median estimator requires that at least 50% of the weight 705 706 in the analysis stems from valid instruments. The MR-Egger estimator assumes that the 707 instrument strength is independent of its the direct effects on the outcome (i.e. INSIDE 708 assumption).

709

In addition to the core assumptions, the two-sample MR approach assumes that genetic associations with exposure and outcome were estimated from two comparable but non-overlapping samples. We restricted our analyses to European adult individuals to ensure that samples were comparable. We assessed potential bias due to sample overlap by conducting MR using SNPs selected from previous GWAS of age at menarche and age at natural menopause that did not include UK Biobank (**Supplementary Table 14**).

#### 717 Acknowledgements

We are extremely grateful to Nightingale for the use of their data and for their helpful 718 discussions throughout. We want to acknowledge participants and investigators from UK 719 Biobank and the multiple large-scale GWAS consortia which made summary data available. 720 This work used the computational facilities of the Advanced Computing Research Centre, 721 722 University of Bristol - http://www.bristol.ac.uk/acrc/. The current analysis was approved under UK Biobank Project 30418 and 81499. We are also grateful to Professor Kate Tilling 723 724 (University of Bristol), Prof Zoltan Kutalik, and Leona Knusel (University of Lausanne) who 725 helped us with additional analyses undertaken to explore discrepant results between multivariable regression and two sample MR for the association of age at natural menopause 726 727 with biomarkers.

# 728 Availability of data and materials

Analysis scripts and the analysis plan can be found on the following GitHub page:https://github.com/gc13313/nmr\_repro.

# 731 Ethical approval and consent to participate

732 UK Biobank received ethical approval from the Research Ethics Committee (REC reference

for UK Biobank is 11/NW/0382). The current analysis was approved under UK Biobank Project30418 and 81499.

#### 735 Funding

This research is supported by the University of Bristol and UK Medical Research Council (MRC) (MC\_UU\_00011/6, all authors), the European Union's Horizon 2020 research and innovation programme under grant agreement No 733206 LifeCycle (GLC and DAL), a University of Bristol Vice-Chancellor's Fellowship (MCB), the British Heart Foundation (AA/18/7/34219, MCB and DAL and CH/F/20/90003, DAL) and the UK National Institute of Health Research (NF-0616-10102, DAL).

The funders had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript. For the purpose of Open Access, the author has applied a CC
BY public copyright licence to any Author Accepted Manuscript version arising from this
submission.

This publication is the work of the authors and all authors will serve as guarantors for the contents of this paper.

# 748 Author contributions

- 749 DAL conceived the study. DAL, MCB and GLC designed the study. MCB and GLC performed
- the analyses. MCB and GLC wrote the original draft of the manuscript with input from DAL. All
- authors were involved in the interpretation of results, helped refine the manuscript, and
- approved its final version.
- 753

# 754 Declarations of Interest

- 755 DAL reports receiving support from several national and international government and charity
- research funders, and grants from Roche Diagnostics and Medtronic Ltd for work unrelated to
- that presented here. GLC and MCB declare that they have no competing interests.
- 758

# 759 Abbreviations

Ala	Alanine
ApoA1	Apolipoprotein A1
АроВ	Apolipoprotein B
ApoB_by_ApoA1	Ratio of apolipoprotein B to apolipoprotein A1
Cholines	Total cholines
Clinical_LDL_C	Clinical LDL cholesterol
DHA	Docosahexaenoic acid
DHA_pct	Ratio of docosahexaenoic acid to total fatty acids
Gln	Glutamine
Gly	Glycine
GlycA	Glycoprotein acetyls
HDL_C	HDL cholesterol
HDL_CE	Cholesteryl esters in HDL
HDL_FC	Free cholesterol in HDL
HDL_L	Total lipids in HDL
HDL_P	Concentration of HDL particles
HDL_PL	Phospholipids in HDL
HDL_TG	Triglycerides in HDL
HDL_size	Average diameter for HDL particles
His	Histidine
IDL_C	Cholesterol in IDL
IDL_CE	Cholesteryl esters in IDL
IDL_CE_pct	Cholesteryl esters to total lipids ratio in IDL
IDL_C_pct	Cholesterol to total lipids ratio in IDL
IDL_FC	Free cholesterol in IDL
IDL_FC_pct	Free cholesterol to total lipids ratio in IDL
IDL_L	Total lipids in IDL
IDL_P	Concentration of IDL particles
IDL_PL	Phospholipids in IDL
IDL_PL_pct	Phospholipids to total lipids ratio in IDL
IDL_TG	Triglycerides in IDL
IDL_TG_pct	Triglycerides to total lipids ratio in IDL
lle	Isoleucine
LA	Linoleic acid

LA pct	Ratio of linoleic acid to total fatty acids
	I DL cholesterol
	Cholesteryl esters in LDI
	Free cholesterol in LDL
	Total linids in LDI
	Concentration of LDL particles
	Phospholinide in LDL
	Average diameter for LDL nerticles
	Average diameter for LDL particles
	Cholesteryl esters in large HDL
L_HDL_CE_pct	Cholesteryl esters to total lipids ratio in large HDL
L_HDL_C_pct	Cholesterol to total lipids ratio in large HDL
L_HDL_FC	Free cholesterol in large HDL
L_HDL_FC_pct	Free cholesterol to total lipids ratio in large HDL
L_HDL_L	Total lipids in large HDL
L_HDL_P	Concentration of large HDL particles
L_HDL_PL	Phospholipids in large HDL
L_HDL_PL_pct	Phospholipids to total lipids ratio in large HDL
L_HDL_TG	Triglycerides in large HDL
L_HDL_TG_pct	Triglycerides to total lipids ratio in large HDL
L LDL C	Cholesterol in large LDL
L LDL CE	Cholesteryl esters in large LDL
L LDL CE pct	Cholesteryl esters to total lipids ratio in large LDL
L LDL C pct	Cholesterol to total lipids ratio in large LDL
	Free cholesterol in large LDL
L LDL FC pct	Free cholesterol to total lipids ratio in large LDL
	Total lipids in large I DI
	Concentration of large LDL particles
	Phospholipids in large I DI
L DI PL pct	Phospholipids to total lipids ratio in large LDL
	Trialycerides in large LDI
L LDL TG pct	Triglycerides to total lipids ratio in large LDL
	Cholesteral in Jarge VI DI
	Cholesterul esters in large VLDL
	Cholesteryl esters in large VLDL
L_VLDL_CE_pct	Cholestery esters to total lipids ratio in large VLDL
	Free cholesterol in large VLDL
	Free cholesterol to total lipids ratio in large VLDL
L_VLDL_P	Concentration of large VLDL particles
L_VLDL_PL	Phospholipids in large VLDL
L_VLDL_PL_pct	Phospholipids to total lipids ratio in large VLDL
L_VLDL_TG	Triglycerides in large VLDL
L_VLDL_TG_pct	Triglycerides to total lipids ratio in large VLDL
Leu	Leucine
MUFA	Monounsaturated fatty acids
MUFA_pct	Ratio of monounsaturated fatty acids to total fatty acids
M_HDL_C	Cholesterol in medium HDL
M_HDL_CE	Cholesteryl esters in medium HDL
M_HDL_CE_pct	Cholesteryl esters to total lipids ratio in medium HDL
M_HDL_C_pct	Cholesterol to total lipids ratio in medium HDL
M_HDL_FC	Free cholesterol in medium HDL
M_HDL_FC_pct	Free cholesterol to total lipids ratio in medium HDL
M_HDL_L	Total lipids in medium HDL

M_HDL_P	Concentration of medium HDL particles
M_HDL_PL	Phospholipids in medium HDL
M_HDL_PL_pct	Phospholipids to total lipids ratio in medium HDL
M_HDL_TG	Triglycerides in medium HDL
M_HDL_TG_pct	Triglycerides to total lipids ratio in medium HDL
M_LDL_C	Cholesterol in medium LDL
M_LDL_CE	Cholesteryl esters in medium LDL
M_LDL_CE_pct	Cholesteryl esters to total lipids ratio in medium LDL
M_LDL_C_pct	Cholesterol to total lipids ratio in medium LDL
M_LDL_FC	Free cholesterol in medium LDL
M_LDL_FC_pct	Free cholesterol to total lipids ratio in medium LDL
M_LDL_L	Total lipids in medium LDL
M_LDL_P	Concentration of medium LDL particles
M_LDL_PL	Phospholipids in medium LDL
M_LDL_PL_pct	Phospholipids to total lipids ratio in medium LDL
M_LDL_TG	Triglycerides in medium LDL
M_LDL_TG_pct	Triglycerides to total lipids ratio in medium LDL
M VLDL C	Cholesterol in medium VLDL
M VLDL CE	Cholesteryl esters in medium VLDL
M VLDL CE pct	Cholesteryl esters to total lipids ratio in medium VLDL
M VLDL C pct	Cholesterol to total lipids ratio in medium VLDL
M VLDL FC	Free cholesterol in medium VLDL
M VLDL FC pct	Free cholesterol to total lipids ratio in medium VLDL
M VLDL L	Total lipids in medium VLDL
M VLDL P	Concentration of medium VLDL particles
M VLDL PL	Phospholipids in medium VLDL
M VLDL PL pct	Phospholipids to total lipids ratio in medium VLDL
M VLDL TG	Triglycerides in medium VLDL
M VLDL TG pct	Triglycerides to total lipids ratio in medium VLDL
Omega 3	Omega-3 fatty acids
Omega 3 pct	Ratio of omega-3 fatty acids to total fatty acids
Omega 6	Omega-6 fatty acids
Omega 6 by Omega 3	Ratio of omega-6 fatty acids to omega-3 fatty acids
Omega 6 pct	Ratio of omega-6 fatty acids to total fatty acids
PUFA	Polyunsaturated fatty acids
PUFA by MUFA	Ratio of polyunsaturated fatty acids to monounsaturated fatty acids
PUFA pct	Ratio of polyunsaturated fatty acids to total fatty acids
Phe	Phenylalanine
Phosphatidvlc	Phosphatidylcholines
Phosphoglyc	Phosphoglycerides
Remnant C	Remnant cholesterol (non-HDL, non-LDL -cholesterol)
SFA	Saturated fatty acids
SFA pct	Ratio of saturated fatty acids to total fatty acids
S HDL C	Cholesterol in small HDL
S HDL CE	Cholesteryl esters in small HDL
S HDL CE pct	Cholestervl esters to total lipids ratio in small HDL
S HDL C pct	Cholesterol to total lipids ratio in small HDL
S HDL FC	Free cholesterol in small HDL
S HDL FC pct	Free cholesterol to total lipids ratio in small HDL
S HDL L	Total lipids in small HDL
S HDL P	Concentration of small HDL particles
S HDL PL	Phospholipids in small HDL
S HDL PL pct	Phospholipids to total lipids ratio in small HDL
S HDL TG	Triglycerides in small HDL
S HDL TG pct	Triglycerides to total lipids ratio in small HDL
<sup>_</sup> I	

S LDL C	Cholesterol in small LDL
SLDLCE	Cholesteryl esters in small LDL
S LDL CE pct	Cholesteryl esters to total lipids ratio in small LDL
S LDL C pct	Cholesterol to total lipids ratio in small LDL
S LDL FC	Free cholesterol in small LDL
S LDL FC pct	Free cholesterol to total lipids ratio in small LDL
	Total lipids in small I DI
SIDI P	Concentration of small I DL particles
S I DI PI	Phospholipids in small I DI
S I DI PI pct	Phospholipids to total lipids ratio in small I DI
	Triglycerides in small I DI
S LDL TG nct	Triglycerides to total linids ratio in small I DI
	Cholesterol in small VI DI
S VIDL CE	Cholesteryl esters in small VI DI
S VLDL_CE_pct	Cholesteryl esters to total linids ratio in small VI DI
S VIDL C pct	Cholesterol to total linide ratio in small VLDL
	Free cholesterol in small VI DI
S_VEDE_IC	Free cholesterol to total linida ratio in small VI DI
	Tetel linide in small VI DI
	Concentration of small VLDL norticles
	Concentration of small VLDL particles
S_VLDL_PL	Phospholipids in small VLDL
S_VLDL_IG	
S_VLDL_IG_pct	I rigiycerides to total lipids ratio in small VLDL
TG_by_PG	Ratio of triglycerides to phosphoglycerides
Total BCAA	I otal concentration of branched-chain amino acids (leucine + isoleucine +
Total_C	Total cholesterol
	I otal esterified cholesterol
	Total fatty acids
	l otal lipids in lipoprotein particles
Iotal_P	I otal concentration of lipoprotein particles
Iotal_PL	I otal phospholipids in lipoprotein particles
Iotal_IG	l otal triglycerides
Tyr	Tyrosine
Unsaturation	Degree of unsaturation
VLDL_C	VLDL cholesterol
VLDL_CE	Cholesteryl esters in VLDL
VLDL_FC	Free cholesterol in VLDL
VLDL_L	Total lipids in VLDL
VLDL_P	Concentration of VLDL particles
VLDL_PL	Phospholipids in VLDL
VLDL_TG	Triglycerides in VLDL
VLDL_size	Average diameter for VLDL particles
Val	Valine
XL_HDL_C	Cholesterol in very large HDL
XL_HDL_CE	Cholesteryl esters in very large HDL
XL_HDL_CE_pct	Cholesteryl esters to total lipids ratio in very large HDL
XL_HDL_C_pct	Cholesterol to total lipids ratio in very large HDL
XL_HDL_FC	Free cholesterol in very large HDL
XL_HDL_FC_pct	Free cholesterol to total lipids ratio in very large HDL
XL_HDL_L	Total lipids in very large HDL
XL_HDL_P	Concentration of very large HDL particles
XL_HDL_PL	Phospholipids in very large HDL

XL HDL PL pct	Phospholipids to total lipids ratio in very large HDL
XL HDL TG	Triglycerides in very large HDL
XL HDL TG pct	Triglycerides to total lipids ratio in very large HDL
XL VLDL C	Cholesterol in very large VLDL
XL_VLDL_CE	Cholesteryl esters in very large VLDL
XL_VLDL_CE pct	Cholesteryl esters to total lipids ratio in very large VLDL
XL VLDL C pct	Cholesterol to total lipids ratio in very large VLDL
XL_VLDL_FC	Free cholesterol in very large VLDL
XL VLDL FC pct	Free cholesterol to total lipids ratio in very large VLDL
XL_VLDL_L	Total lipids in very large VLDL
XL_VLDL_P	Concentration of very large VLDL particles
XL_VLDL_PL	Phospholipids in very large VLDL
XL_VLDL_PL_pct	Phospholipids to total lipids ratio in very large VLDL
XL_VLDL_TG	Triglycerides in very large VLDL
XL_VLDL_TG_pct	Triglycerides to total lipids ratio in very large VLDL
XS_VLDL_C	Cholesterol in very small VLDL
XS_VLDL_CE	Cholesteryl esters in very small VLDL
XS_VLDL_CE_pct	Cholesteryl esters to total lipids ratio in very small VLDL
XS_VLDL_C_pct	Cholesterol to total lipids ratio in very small VLDL
XS_VLDL_FC	Free cholesterol in very small VLDL
XS_VLDL_FC_pct	Free cholesterol to total lipids ratio in very small VLDL
XS_VLDL_L	Total lipids in very small VLDL
XS_VLDL_P	Concentration of very small VLDL particles
XS_VLDL_PL	Phospholipids in very small VLDL
XS_VLDL_PL_pct	Phospholipids to total lipids ratio in very small VLDL
XS_VLDL_TG	Triglycerides in very small VLDL
XS_VLDL_TG_pct	Triglycerides to total lipids ratio in very small VLDL
XXL_VLDL_C	Cholesterol in chylomicrons and extremely large VLDL
XXL_VLDL_CE	Cholesteryl esters in chylomicrons and extremely large VLDL
XXL_VLDL_CE_pct	Cholesteryl esters to total lipids ratio in chylomicrons and extremely large VLDL
XXL_VLDL_C_pct	Cholesterol to total lipids ratio in chylomicrons and extremely large VLDL
XXL_VLDL_FC	Free cholesterol in chylomicrons and extremely large VLDL
XXL_VLDL_FC_pct	Free cholesterol to total lipids ratio in chylomicrons and extremely large VLDL
XXL_VLDL_L	Total lipids in chylomicrons and extremely large VLDL
XXL_VLDL_P	Concentration of chylomicrons and extremely large VLDL particles
XXL_VLDL_PL	Phospholipids in chylomicrons and extremely large VLDL
XXL_VLDL_PL_pct	Phospholipids to total lipids ratio in chylomicrons and extremely large VLDL
XXL_VLDL_TG	Triglycerides in chylomicrons and extremely large VLDL
XXL_VLDL_TG_pct	Triglycerides to total lipids ratio in chylomicrons and extremely large VLDL
bOHbutyrate	3-Hydroxybutyrate
non_HDL_C	Total cholesterol minus HDL-C

760

# 761 **References**

762

763	1	Ness, R. B., Schotland, H. M., Flegal, K. M. & Shofer, F. S. Reproductive History and Coronary
764		Heart Disease Risk in Women. Epidemiologic Reviews 16, 298-314 (1994).
765		https://doi.org:10.1093/oxfordjournals.epirev.a036155
766	2	Canoy, D. et al. Age at Menarche and Risks of Coronary Heart and Other Vascular Diseases in
767		a Large UK Cohort. Circulation 131, 237-244 (2015).
768		https://doi.org:10.1161/CIRCULATIONAHA.114.010070
769	3	Cooper, G. S. et al. Menstrual and Reproductive Risk Factors for Ischemic Heart Disease.
770		Epidemiology <b>10</b> , 255-259 (1999).

771	4	Green, A., Beral, V. & Moser, K. Mortality in women in relation to their childbearing history.
772		British Medical Journal 297, 391 (1988). <u>https://doi.org:10.1136/bmj.297.6645.391</u>
773	5	Lawlor Debbie, A. et al. Is the Association Between Parity and Coronary Heart Disease Due to
774		Biological Effects of Pregnancy or Adverse Lifestyle Risk Factors Associated With Child-
775		Rearing? Circulation 107, 1260-1264 (2003).
776		https://doi.org:10.1161/01.CIR.0000053441.43495.1A
777	6	Colditz, G. A. et al. A PROSPECTIVE STUDY OF AGE AT MENARCHE, PARITY, AGE AT FIRST
778		BIRTH, AND CORONARY HEART DISEASE IN WOMEN. American Journal of Epidemiology 126,
779		861-870 (1987). <u>https://doi.org:10.1093/oxfordjournals.aje.a114723</u>
780	7	Kelsey, J. L., Gammon, M. D. & John, E. M. Reproductive Factors and Breast Cancer.
781		Epidemiologic Reviews <b>15</b> , 36-47 (1993).
782		https://doi.org:10.1093/oxfordjournals.epirev.a036115
783	8	Lambe, M. et al. Parity, age at first and last birth, and risk of breast cancer: A population-
784		based study in Sweden. Breast Cancer Research and Treatment 38, 305-311 (1996).
785		https://doi.org:10.1007/BF01806150
786	9	Gong, TT., Wu, QJ., Vogtmann, E., Lin, B. & Wang, YL. Age at menarche and risk of
787		ovarian cancer: a meta-analysis of epidemiological studies. Int J Cancer 132, 2894-2900
788		(2013). <u>https://doi.org:10.1002/ijc.27952</u>
789	10	Whiteman, D. C., Siskind, V., Purdie, D. M. & Green, A. C. Timing of Pregnancy and the Risk of
790		Epithelial Ovarian Cancer. Cancer Epidemiology Biomarkers & amp; amp; Prevention 12, 42
791		(2003).
792	11	Adami, H. O. et al. Parity, age at first childbirth, and risk of ovarian cancer. The Lancet 344,
793		1250-1254 (1994). <u>https://doi.org:https://doi.org/10.1016/S0140-6736(94)90749-8</u>
794	12	Dossus, L. et al. Reproductive risk factors and endometrial cancer: the European Prospective
795		Investigation into Cancer and Nutrition. Int J Cancer <b>127</b> , 442-451 (2010).
796		https://doi.org:https://doi.org/10.1002/ijc.25050
797	13	Burgess, S. et al. Dissecting Causal Pathways Using Mendelian Randomization with
798		Summarized Genetic Data: Application to Age at Menarche and Risk of Breast Cancer.
799		Genetics 207, 481-487 (2017). https://doi.org:10.1534/genetics.117.300191
800	14	Mumby, H. S. <i>et al.</i> Mendelian Randomisation Study of Childhood BMI and Early Menarche.
801		lowersh of Obasity 2011, 190720 (2011), https://doi.org/10.1155/2011/190720
802		Journal of Obesity <b>2011</b> , 180729 (2011). <u>https://doi.org/10.1155/2011/180729</u>
	15	Mills, M. C. <i>et al.</i> Identification of 370 loci for age at onset of sexual and reproductive
803	15	Mills, M. C. <i>et al.</i> Identification of 370 loci for age at onset of sexual and reproductive behaviour, highlighting common aetiology with reproductive biology, externalizing
803 804	15	Mills, M. C. <i>et al.</i> Identification of 370 loci for age at onset of sexual and reproductive behaviour, highlighting common aetiology with reproductive biology, externalizing behaviour and longevity. <i>bioRxiv</i> , 2020.2005.2006.081273 (2020).
803 804 805	15	Mills, M. C. <i>et al.</i> Identification of 370 loci for age at onset of sexual and reproductive behaviour, highlighting common aetiology with reproductive biology, externalizing behaviour and longevity. <i>bioRxiv</i> , 2020.2005.2006.081273 (2020). https://doi.org:10.1101/2020.05.06.081273
803 804 805 806	15 16	Mills, M. C. <i>et al.</i> Identification of 370 loci for age at onset of sexual and reproductive behaviour, highlighting common aetiology with reproductive biology, externalizing behaviour and longevity. <i>bioRxiv</i> , 2020.2005.2006.081273 (2020). https://doi.org:10.1101/2020.05.06.081273 Barban, N. <i>et al.</i> Genome-wide analysis identifies 12 loci influencing human reproductive
803 804 805 806 807	15 16	Mills, M. C. <i>et al.</i> Identification of 370 loci for age at onset of sexual and reproductive behaviour, highlighting common aetiology with reproductive biology, externalizing behaviour and longevity. <i>bioRxiv</i> , 2020.2005.2006.081273 (2020). https://doi.org:10.1101/2020.05.06.081273 Barban, N. <i>et al.</i> Genome-wide analysis identifies 12 loci influencing human reproductive behavior. <i>Nature genetics</i> <b>48</b> , 1462-1472 (2016). https://doi.org:10.1038/ng.3698
803 804 805 806 807 808	15 16 17	Mills, M. C. <i>et al.</i> Identification of 370 loci for age at onset of sexual and reproductive behaviour, highlighting common aetiology with reproductive biology, externalizing behaviour and longevity. <i>bioRxiv</i> , 2020.2005.2006.081273 (2020). https://doi.org:10.1101/2020.05.06.081273 Barban, N. <i>et al.</i> Genome-wide analysis identifies 12 loci influencing human reproductive behavior. <i>Nature genetics</i> <b>48</b> , 1462-1472 (2016). https://doi.org:10.1038/ng.3698 Ruth, K. S. <i>et al.</i> Genetic insights into the biological mechanisms governing human ovarian
803 804 805 806 807 808 809	15 16 17	<ul> <li>Mills, M. C. <i>et al.</i> Identification of 370 loci for age at onset of sexual and reproductive behaviour, highlighting common aetiology with reproductive biology, externalizing behaviour and longevity. <i>bioRxiv</i>, 2020.2005.2006.081273 (2020).</li> <li><a href="https://doi.org:10.1101/2020.05.06.081273">https://doi.org:10.1101/2020.05.06.081273</a></li> <li>Barban, N. <i>et al.</i> Genome-wide analysis identifies 12 loci influencing human reproductive behavior. <i>Nature genetics</i> 48, 1462-1472 (2016). <a href="https://doi.org:10.1038/ng.3698">https://doi.org:10.1038/ng.3698</a></li> <li>Ruth, K. S. <i>et al.</i> Genetic insights into the biological mechanisms governing human ovarian ageing. <i>medRxiv</i>, 2021.2001.2011.20248322 (2021).</li> </ul>
803 804 805 806 807 808 809 810	15 16 17	Mills, M. C. <i>et al.</i> Identification of 370 loci for age at onset of sexual and reproductive behaviour, highlighting common aetiology with reproductive biology, externalizing behaviour and longevity. <i>bioRxiv</i> , 2020.2005.2006.081273 (2020). https://doi.org:10.1101/2020.05.06.081273 Barban, N. <i>et al.</i> Genome-wide analysis identifies 12 loci influencing human reproductive behavior. <i>Nature genetics</i> <b>48</b> , 1462-1472 (2016). https://doi.org:10.1038/ng.3698 Ruth, K. S. <i>et al.</i> Genetic insights into the biological mechanisms governing human ovarian ageing. <i>medRxiv</i> , 2021.2001.2011.20248322 (2021). https://doi.org:10.1101/2021.01.11.20248322
803 804 805 806 807 808 809 810 811	15 16 17 18	Journal of Obesity 2011, 180729 (2011). <a href="https://doi.org/10.1155/2011/180729">https://doi.org/10.1155/2011/180729</a> Mills, M. C. et al. Identification of 370 loci for age at onset of sexual and reproductivebehaviour, highlighting common aetiology with reproductive biology, externalizingbehaviour and longevity. bioRxiv, 2020.2005.2006.081273 (2020).https://doi.org:10.1101/2020.05.06.081273Barban, N. et al. Genome-wide analysis identifies 12 loci influencing human reproductivebehavior. Nature genetics 48, 1462-1472 (2016). <a href="https://doi.org:10.1038/ng.3698">https://doi.org:10.1038/ng.3698</a> Ruth, K. S. et al. Genetic insights into the biological mechanisms governing human ovarianageing. medRxiv, 2021.2001.2011.20248322 (2021).https://doi.org:10.1101/2021.01.11.20248322Wurtz, P. et al. Quantitative Serum Nuclear Magnetic Resonance Metabolomics in Large-
803 804 805 806 807 808 809 810 811 812	15 16 17 18	<ul> <li>Mills, M. C. <i>et al.</i> Identification of 370 loci for age at onset of sexual and reproductive behaviour, highlighting common aetiology with reproductive biology, externalizing behaviour and longevity. <i>bioRxiv</i>, 2020.2005.2006.081273 (2020).</li> <li><a href="https://doi.org:10.1101/2020.05.06.081273">https://doi.org:10.1101/2020.05.06.081273</a></li> <li>Barban, N. <i>et al.</i> Genome-wide analysis identifies 12 loci influencing human reproductive behavior. <i>Nature genetics</i> 48, 1462-1472 (2016). <a href="https://doi.org:10.1038/ng.3698">https://doi.org:10.1038/ng.3698</a></li> <li>Ruth, K. S. <i>et al.</i> Genetic insights into the biological mechanisms governing human ovarian ageing. <i>medRxiv</i>, 2021.2001.2011.20248322 (2021).</li> <li><a href="https://doi.org:10.1101/2021.01.11.20248322">https://doi.org:10.1101/2021.01.11.20248322</a></li> <li>Wurtz, P. <i>et al.</i> Quantitative Serum Nuclear Magnetic Resonance Metabolomics in Large-Scale Epidemiology: A Primer on -Omic Technologies. <i>Am J Epidemiol</i> 186, 1084-1096 (2017).</li> </ul>
803 804 805 806 807 808 809 810 811 812 813	15 16 17 18	Mills, M. C. <i>et al.</i> Identification of 370 loci for age at onset of sexual and reproductive behaviour, highlighting common aetiology with reproductive biology, externalizing behaviour and longevity. <i>bioRxiv</i> , 2020.2005.2006.081273 (2020). https://doi.org:10.1101/2020.05.06.081273 Barban, N. <i>et al.</i> Genome-wide analysis identifies 12 loci influencing human reproductive behavior. <i>Nature genetics</i> <b>48</b> , 1462-1472 (2016). https://doi.org:10.1038/ng.3698 Ruth, K. S. <i>et al.</i> Genetic insights into the biological mechanisms governing human ovarian ageing. <i>medRxiv</i> , 2021.2001.2011.20248322 (2021). https://doi.org:10.1101/2021.01.11.20248322 Wurtz, P. <i>et al.</i> Quantitative Serum Nuclear Magnetic Resonance Metabolomics in Large- Scale Epidemiology: A Primer on -Omic Technologies. <i>Am J Epidemiol</i> <b>186</b> , 1084-1096 (2017). https://doi.org:10.1093/aje/kwx016
803 804 805 806 807 808 809 810 811 812 813 814	15 16 17 18 19	<ul> <li>Mills, M. C. <i>et al.</i> Identification of 370 loci for age at onset of sexual and reproductive behaviour, highlighting common aetiology with reproductive biology, externalizing behaviour and longevity. <i>bioRxiv</i>, 2020.2005.2006.081273 (2020).</li> <li><a href="https://doi.org:10.1101/2020.05.06.081273">https://doi.org:10.1101/2020.05.06.081273</a></li> <li>Barban, N. <i>et al.</i> Genome-wide analysis identifies 12 loci influencing human reproductive behavior. <i>Nature genetics</i> 48, 1462-1472 (2016). <a href="https://doi.org:10.1038/ng.3698">https://doi.org:10.1038/ng.3698</a></li> <li>Ruth, K. S. <i>et al.</i> Genetic insights into the biological mechanisms governing human ovarian ageing. <i>medRxiv</i>, 2021.2001.2011.20248322 (2021).</li> <li><a href="https://doi.org:10.1101/2021.01.11.20248322">https://doi.org:10.101/2021.01.11.20248322</a></li> <li>Wurtz, P. <i>et al.</i> Quantitative Serum Nuclear Magnetic Resonance Metabolomics in Large-Scale Epidemiology: A Primer on -Omic Technologies. <i>Am J Epidemiol</i> 186, 1084-1096 (2017).</li> <li><a href="https://doi.org:10.1093/aje/kwx016">https://doi.org:10.1093/aje/kwx016</a></li> <li>Würtz, P. <i>et al.</i> Metabolite profiling and cardiovascular event risk: a prospective study of 3</li> </ul>
803 804 805 806 807 808 809 810 811 812 813 814 815	15 16 17 18 19	<ul> <li>Mills, M. C. <i>et al.</i> Identification of 370 loci for age at onset of sexual and reproductive behaviour, highlighting common aetiology with reproductive biology, externalizing behaviour and longevity. <i>bioRxiv</i>, 2020.2005.2006.081273 (2020).</li> <li><a href="https://doi.org:10.1101/2020.05.06.081273">https://doi.org:10.1101/2020.05.06.081273</a></li> <li>Barban, N. <i>et al.</i> Genome-wide analysis identifies 12 loci influencing human reproductive behavior. <i>Nature genetics</i> 48, 1462-1472 (2016). <a href="https://doi.org:10.1038/ng.3698">https://doi.org:10.1038/ng.3698</a></li> <li>Ruth, K. S. <i>et al.</i> Genetic insights into the biological mechanisms governing human ovarian ageing. <i>medRxiv</i>, 2021.2001.2011.20248322 (2021).</li> <li><a href="https://doi.org:10.1101/2021.01.11.20248322">https://doi.org:10.1038/ng.3698</a></li> <li><a href="https://doi.org:10.1101/2021.01.11.20248322">https://doi.org:10.1038/ng.3698</a></li> <li><a href="https://doi.org:10.1101/2021.01.11.20248322">https://doi.org:10.1038/ng.3698</a></li> <li><a href="https://doi.org:10.1101/2021.01.11.20248322">https://doi.org:10.1038/ng.3698</a></li> <li><a href="https://doi.org:10.1101/2021.01.11.20248322">https://doi.org:10.1038/ng.3698</a></li> <li><a href="https://doi.org:10.1101/2021.01.11.20248322">https://doi.org:10.1038/ng.3698</a></li> <li><a href="https://doi.org:10.1101/2021.01.11.20248322">https://doi.org:10.101/2021.01.11.20248322</a></li> <li><a href="https://doi.org:10.1101/2021.01.11.20248322">https://doi.org:10.1101/2021.01.11.20248322</a></li> <li><a href="https://doi.org:10.1093/aje/kwx016">https://doi.org:10.1093/aje/kwx016</a></li> <li><a href="https://doi.org:10.1093/aje/kwx016">https://doi.org:10.1093/aje/kwx016</a></li> <li><a href="https://doi.org:10.1093/aje/kwx016">https://doi.org:10.1093/aje/kwx016</a></li> <li><a href="https://doi.org:10.1131">https://doi.org:10.1031</a>, 774-785 (2015).</li> </ul>
803 804 805 806 807 808 809 810 811 812 813 814 815 816	15 16 17 18 19	<ul> <li>Mills, M. C. <i>et al.</i> Identification of 370 loci for age at onset of sexual and reproductive behaviour, highlighting common aetiology with reproductive biology, externalizing behaviour and longevity. <i>bioRxiv</i>, 2020.2005.2006.081273 (2020).</li> <li>https://doi.org:10.1101/2020.05.06.081273</li> <li>Barban, N. <i>et al.</i> Genome-wide analysis identifies 12 loci influencing human reproductive behavior. <i>Nature genetics</i> 48, 1462-1472 (2016). https://doi.org:10.1038/ng.3698</li> <li>Ruth, K. S. <i>et al.</i> Genetic insights into the biological mechanisms governing human ovarian ageing. <i>medRxiv</i>, 2021.2001.2011.20248322 (2021).</li> <li>https://doi.org:10.1101/2021.01.11.20248322</li> <li>Wurtz, P. <i>et al.</i> Quantitative Serum Nuclear Magnetic Resonance Metabolomics in Large-Scale Epidemiology: A Primer on -Omic Technologies. <i>Am J Epidemiol</i> 186, 1084-1096 (2017).</li> <li>https://doi.org:10.1093/aje/kwx016</li> <li>Würtz, P. <i>et al.</i> Metabolite profiling and cardiovascular event risk: a prospective study of 3 population-based cohorts. <i>Circulation</i> 131, 774-785 (2015).</li> <li>https://doi.org:10.1161/CIRCULATIONAHA.114.013116</li> </ul>
803 804 805 806 807 808 809 810 811 812 813 814 815 816 817	15 16 17 18 19 20	<ul> <li>Mills, M. C. <i>et al.</i> Identification of 370 loci for age at onset of sexual and reproductive behaviour, highlighting common aetiology with reproductive biology, externalizing behaviour and longevity. <i>bioRxiv</i>, 2020.2005.2006.081273 (2020).</li> <li><a href="https://doi.org:10.1101/2020.05.06.081273">https://doi.org:10.1101/2020.05.06.081273</a></li> <li>Barban, N. <i>et al.</i> Genome-wide analysis identifies 12 loci influencing human reproductive behavior. <i>Nature genetics</i> <b>48</b>, 1462-1472 (2016). <a href="https://doi.org:10.1038/ng.3698">https://doi.org:10.1038/ng.3698</a></li> <li>Ruth, K. S. <i>et al.</i> Genetic insights into the biological mechanisms governing human ovarian ageing. <i>medRxiv</i>, 2021.2001.2011.20248322 (2021).</li> <li><a href="https://doi.org:10.1101/2021.01.11.20248322">https://doi.org:10.1038/ng.3698</a></li> <li>Wurtz, P. <i>et al.</i> Quantitative Serum Nuclear Magnetic Resonance Metabolomics in Large-Scale Epidemiology: A Primer on -Omic Technologies. <i>Am J Epidemiol</i> <b>186</b>, 1084-1096 (2017).</li> <li><a href="https://doi.org:10.1161/CIRCULATIONAHA.114.013116">https://doi.org:10.1161/CIRCULATIONAHA.114.013116</a></li> <li>Wang, Q. <i>et al.</i> Metabolic profiling of pregnancy: cross-sectional and longitudinal evidence.</li> </ul>
803 804 805 806 807 808 809 810 811 812 813 814 815 816 817 818	15 16 17 18 19 20	<ul> <li>Mills, M. C. <i>et al.</i> Identification of 370 loci for age at onset of sexual and reproductive behaviour, highlighting common aetiology with reproductive biology, externalizing behaviour and longevity. <i>bioRxiv</i>, 2020.2005.2006.081273 (2020).</li> <li>https://doi.org:10.1101/2020.05.06.081273</li> <li>Barban, N. <i>et al.</i> Genome-wide analysis identifies 12 loci influencing human reproductive behavior. <i>Nature genetics</i> 48, 1462-1472 (2016). https://doi.org:10.1038/ng.3698</li> <li>Ruth, K. S. <i>et al.</i> Genetic insights into the biological mechanisms governing human ovarian ageing. <i>medRxiv</i>, 2021.2001.2011.20248322 (2021).</li> <li>https://doi.org:10.1101/2021.01.11.20248322</li> <li>Wurtz, P. <i>et al.</i> Quantitative Serum Nuclear Magnetic Resonance Metabolomics in Large-Scale Epidemiology: A Primer on -Omic Technologies. <i>Am J Epidemiol</i> 186, 1084-1096 (2017).</li> <li>https://doi.org:10.1093/aje/kwx016</li> <li>Würtz, P. <i>et al.</i> Metabolite profiling and cardiovascular event risk: a prospective study of 3 population-based cohorts. <i>Circulation</i> 131, 774-785 (2015).</li> <li>https://doi.org:10.1161/CIRCULATIONAHA.114.013116</li> <li>Wang, Q. <i>et al.</i> Metabolic profiling of pregnancy: cross-sectional and longitudinal evidence.</li> <li><i>BMC Medicine</i> 14, 205 (2016). https://doi.org:10.1186/s12916-016-0733-0</li> </ul>
803 804 805 806 807 808 809 810 811 812 813 814 815 816 817 818 819	15 16 17 18 19 20 21	<ul> <li>Mills, M. C. <i>et al.</i> Identification of 370 loci for age at onset of sexual and reproductive behaviour, highlighting common aetiology with reproductive biology, externalizing behaviour and longevity. <i>bioRxiv</i>, 2020.2005.2006.081273 (2020).</li> <li>https://doi.org:10.1101/2020.05.06.081273</li> <li>Barban, N. <i>et al.</i> Genome-wide analysis identifies 12 loci influencing human reproductive behavior. <i>Nature genetics</i> 48, 1462-1472 (2016). https://doi.org:10.1038/ng.3698</li> <li>Ruth, K. S. <i>et al.</i> Genetic insights into the biological mechanisms governing human ovarian ageing. <i>medRxiv</i>, 2021.2001.2011.20248322 (2021).</li> <li>https://doi.org:10.1101/2021.01.11.20248322</li> <li>Wurtz, P. <i>et al.</i> Quantitative Serum Nuclear Magnetic Resonance Metabolomics in Large-Scale Epidemiology: A Primer on -Omic Technologies. <i>Am J Epidemiol</i> 186, 1084-1096 (2017).</li> <li>https://doi.org:10.1103/aje/kwx016</li> <li>Würtz, P. <i>et al.</i> Metabolite profiling and cardiovascular event risk: a prospective study of 3 population-based cohorts. <i>Circulation</i> 131, 774-785 (2015).</li> <li>https://doi.org:10.1161/CIRCULATIONAHA.114.013116</li> <li>Wang, Q. <i>et al.</i> Metabolic profiling of pregnancy: cross-sectional and longitudinal evidence.</li> <li><i>BMC Medicine</i> 14, 205 (2016). https://doi.org:10.1186/s12916-016-0733-0</li> <li>Wang, Q. <i>et al.</i> Metabolic characterization of menopause: cross-sectional and longitudinal</li> </ul>

821	22	Wang, Q. et al. Effects of hormonal contraception on systemic metabolism: cross-sectional
822		and longitudinal evidence. International journal of epidemiology <b>45</b> , 1445-1457 (2016).
823		https://doi.org:10.1093/ije/dyw147
824	23	Lane, A. N., Higashi, R. M. & Fan, T. W. M. NMR and MS-based Stable Isotope-Resolved
825		Metabolomics and Applications in Cancer Metabolism. Trends Analyt Chem 120, 115322
826		(2019). <u>https://doi.org:10.1016/j.trac.2018.11.020</u>
827	24	Johnson, K. E. et al. The relationship between circulating lipids and breast cancer risk: A
828		Mendelian randomization study. PLoS medicine 17, e1003302-e1003302 (2020).
829		https://doi.org:10.1371/journal.pmed.1003302
830	25	Chen, W., Wang, S., Lv, W. & Pan, Y. Causal associations of insulin resistance with coronary
831		artery disease and ischemic stroke: a Mendelian randomization analysis. BMJ Open Diabetes
832		Research & amp; Care 8, e001217 (2020). <u>https://doi.org:10.1136/bmjdrc-2020-001217</u>
833	26	Xu, L., Borges, M. C., Hemani, G. & Lawlor, D. A. The role of glycaemic and lipid risk factors in
834		mediating the effect of BMI on coronary heart disease: a two-step, two-sample Mendelian
835		randomisation study. <i>Diabetologia</i> 60, 2210-2220 (2017). <u>https://doi.org:10.1007/s00125-</u>
836		<u>017-4396-y</u>
837	27	Lawlor, D. A., Tilling, K. & Davey Smith, G. Triangulation in aetiological epidemiology.
838		International Journal of Epidemiology <b>45</b> , 1866-1886 (2016).
839		https://doi.org:10.1093/ije/dyw314
840	28	Bell, J. A. <i>et al.</i> Influence of puberty timing on adiposity and cardiometabolic traits: A
841		Mendelian randomisation study. <i>PLoS medicine</i> <b>15</b> . e1002641-e1002641 (2018).
842		https://doi.org:10.1371/journal.pmed.1002641
843	29	Kirkpatrick, R. M., McGue, M., Jacono, W. G., Miller, M. B. & Basu, S. Results of a "GWAS
844		Plus:" General Cognitive Ability Is Substantially Heritable and Massively Polygenic. PLOS ONE
845		<b>9</b> . e112390 (2014). https://doi.org:10.1371/journal.pone.0112390
846	30	Rich-Edwards, J. W., Fraser, A., Lawlor, D. A. & Catov, J. M. Pregnancy Characteristics and
847		Women's Future Cardiovascular Health: An Underused Opportunity to Improve Women's
848		Health? <i>Epidemiologic Reviews</i> <b>36</b> , 57-70 (2014), https://doi.org:10.1093/epirev/mxt006
849	31	Sattar, N. & Greer, I. A. Pregnancy complications and maternal cardiovascular risk:
850	-	opportunities for intervention and screening? BMI (Clinical research ed.) <b>325</b> , 157-160
851		(2002) https://doi.org/10.1136/bmi.325.7356.157
852	32	Li W Ruan W Lu 7 & Wang D Parity and risk of maternal cardiovascular disease. A
853	52	dose-response meta-analysis of cohort studies. <i>European Journal of Preventive Cardiology</i>
854		<b>26</b> 592-602 (2019) https://doi.org/10.1177/2047487318818265
855	33	Hardy R Lawlor D A Black S Wadsworth M E L & Kub D Number of children and
856	55	coronary heart disease risk factors in men and women from a British hirth cohort BIOG: An
857		International Journal of Obstetrics & Gynaecology <b>114</b> , 721-730 (2007)
858		https://doi.org/https://doi.org/10.1111/j.1471-0528.2007.01324.x
850	3/	Bridger Staatz, C & Hardy, B. Number of children and body composition in later life among
860	54	men and women: Results from a British birth cohort study, PLOS ONE 14, e0200529 (2010)
861		https://doi.org:10.1271/journal.pone.0200529
062	25	<u>Sundarson</u> E. B. <i>et al.</i> Childhoaring is associated with higher incidence of the metabolic
002	55	Sunderson, E. P. et al. Childbearing is associated with higher incidence of the metabolic
005		syndrome among women of reproductive age controlling for measurements before
004 965		177 o171 177 o170 (2000) https://doi.org/https://doi.org/10.1016/j.ajog.2000.02.021
80J 866	26	Markovitz, A. B. et al. Doos programov alter life course linid trajectories? Evidence from the
000	50	Walkovitz, A. R. <i>et al.</i> Does pregnancy alter me-course lipid trajectories: Evidence from the
00/		10007 Study in Norway. Journal of inpla rescurch <b>53</b> , 2403-2412 (2018).
000 060	27	Neth K at al Accordition between the conceductive health of yours were and
200 070	57	oxotti, x. et al. Association between the reproductive health of young women and
0/U 071		caruiovascular uisease in later nie. ultiprella review. <i>Bivij</i> <b>371</b> , (113502 (2020).
0/1		<u>mtps://doi.org:10.1136/bmj.m3502</u>

872	38	de Kat, A. C. et al. Unraveling the associations of age and menopause with cardiovascular
873		risk factors in a large population-based study. BMC Medicine <b>15</b> , 2 (2017).
874		https://doi.org:10.1186/s12916-016-0762-8
875	39	Auro, K. et al. A metabolic view on menopause and ageing. Nature Communications 5, 4708
876		(2014). <u>https://doi.org:10.1038/ncomms5708</u>
877	40	Karppinen, J. E. <i>et al.</i> Menopause modulates the circulating metabolome: evidence from a
878		prospective cohort study. <i>medRxiv</i> , 2021.2012.2017.21266891 (2021).
879		https://doi.org:10.1101/2021.12.17.21266891
880	41	Clayton, G. L. et al. Cardiovascular health in the menopause transition: a longitudinal study
881		of up to 3892 women with up to four repeated measures of risk factors. BMC Medicine 20,
882		299 (2022). https://doi.org:10.1186/s12916-022-02454-6
883	42	Matthews, K. A. et al. Are Changes in Cardiovascular Disease Risk Factors in Midlife Women
884		Due to Chronological Aging or to the Menopausal Transition? Journal of the American
885		College of Cardiology <b>54</b> , 2366-2373 (2009).
886		https://doi.org:https://doi.org/10.1016/j.jacc.2009.10.009
887	43	Ruth, K. S. <i>et al.</i> Genetic insights into biological mechanisms governing human ovarian
888		ageing. Nature 596, 393-397 (2021). https://doi.org:10.1038/s41586-021-03779-7
889	44	Salpeter, S. R. <i>et al.</i> Meta-analysis: effect of hormone-replacement therapy on components
890		of the metabolic syndrome in postmenopausal women. <i>Diabetes, Obesity and Metabolism</i> 8,
891		538-554 (2006). https://doi.org:https://doi.org/10.1111/j.1463-1326.2005.00545.x
892	45	Manson, J. E. <i>et al.</i> Menopausal Hormone Therapy and Health Outcomes During the
893		Intervention and Extended Poststopping Phases of the Women's Health Initiative
894		Randomized Trials. JAMA <b>310</b> , 1353-1368 (2013). https://doi.org:10.1001/jama.2013.278040
895	46	Gartlehner, G. et al. U.S. Preventive Services Task Force Evidence Syntheses, formerly
896		Systematic Evidence Reviews (Agency for Healthcare Research and Quality (US), Rockville
897		(MD), 2017).
898	47	Day, F. R. <i>et al.</i> Large-scale genomic analyses link reproductive aging to hypothalamic
899		signaling, breast cancer susceptibility and BRCA1-mediated DNA repair. <i>Nature Genetics</i> <b>47</b> ,
900		1294-1303 (2015). https://doi.org:10.1038/ng.3412
901	48	Munafò, M. R., Tilling, K., Taylor, A. E., Evans, D. M. & Davey Smith, G. Collider scope: when
901 902	48	Munafò, M. R., Tilling, K., Taylor, A. E., Evans, D. M. & Davey Smith, G. Collider scope: when selection bias can substantially influence observed associations. <i>International Journal of</i>
901 902 903	48	Munafò, M. R., Tilling, K., Taylor, A. E., Evans, D. M. & Davey Smith, G. Collider scope: when selection bias can substantially influence observed associations. <i>International Journal of Epidemiology</i> <b>47</b> , 226-235 (2018). https://doi.org:10.1093/ije/dyx206
901 902 903 904	48 49	Munafò, M. R., Tilling, K., Taylor, A. E., Evans, D. M. & Davey Smith, G. Collider scope: when selection bias can substantially influence observed associations. <i>International Journal of Epidemiology</i> <b>47</b> , 226-235 (2018). <u>https://doi.org:10.1093/ije/dyx206</u> Soininen, P., Kangas, A. J., Würtz, P., Suna, T. & Ala-Korpela, M. Quantitative Serum Nuclear
901 902 903 904 905	48 49	Munafò, M. R., Tilling, K., Taylor, A. E., Evans, D. M. & Davey Smith, G. Collider scope: when selection bias can substantially influence observed associations. <i>International Journal of</i> <i>Epidemiology</i> <b>47</b> , 226-235 (2018). <u>https://doi.org:10.1093/ije/dyx206</u> Soininen, P., Kangas, A. J., Würtz, P., Suna, T. & Ala-Korpela, M. Quantitative Serum Nuclear Magnetic Resonance Metabolomics in Cardiovascular Epidemiology and Genetics.
901 902 903 904 905 906	48 49	Munafò, M. R., Tilling, K., Taylor, A. E., Evans, D. M. & Davey Smith, G. Collider scope: when selection bias can substantially influence observed associations. <i>International Journal of</i> <i>Epidemiology</i> <b>47</b> , 226-235 (2018). <u>https://doi.org:10.1093/ije/dyx206</u> Soininen, P., Kangas, A. J., Würtz, P., Suna, T. & Ala-Korpela, M. Quantitative Serum Nuclear Magnetic Resonance Metabolomics in Cardiovascular Epidemiology and Genetics. <i>Circulation: Cardiovascular Genetics</i> <b>8</b> , 192-206 (2015).
901 902 903 904 905 906 907	48 49	Munafò, M. R., Tilling, K., Taylor, A. E., Evans, D. M. & Davey Smith, G. Collider scope: when selection bias can substantially influence observed associations. <i>International Journal of</i> <i>Epidemiology</i> <b>47</b> , 226-235 (2018). <u>https://doi.org:10.1093/ije/dyx206</u> Soininen, P., Kangas, A. J., Würtz, P., Suna, T. & Ala-Korpela, M. Quantitative Serum Nuclear Magnetic Resonance Metabolomics in Cardiovascular Epidemiology and Genetics. <i>Circulation: Cardiovascular Genetics</i> <b>8</b> , 192-206 (2015). https://doi.org:10.1161/CIRCGENETICS.114.000216
901 902 903 904 905 906 907 908	48 49 50	Munafò, M. R., Tilling, K., Taylor, A. E., Evans, D. M. & Davey Smith, G. Collider scope: when selection bias can substantially influence observed associations. <i>International Journal of</i> <i>Epidemiology</i> <b>47</b> , 226-235 (2018). <u>https://doi.org:10.1093/ije/dyx206</u> Soininen, P., Kangas, A. J., Würtz, P., Suna, T. & Ala-Korpela, M. Quantitative Serum Nuclear Magnetic Resonance Metabolomics in Cardiovascular Epidemiology and Genetics. <i>Circulation: Cardiovascular Genetics</i> <b>8</b> , 192-206 (2015). <u>https://doi.org:10.1161/CIRCGENETICS.114.000216</u> Allen, N. E., Sudlow, C., Peakman, T., Collins, R. & Biobank, U. K. UK biobank data: come and
901 902 903 904 905 906 907 908 909	48 49 50	Munafò, M. R., Tilling, K., Taylor, A. E., Evans, D. M. & Davey Smith, G. Collider scope: when selection bias can substantially influence observed associations. <i>International Journal of</i> <i>Epidemiology</i> <b>47</b> , 226-235 (2018). <u>https://doi.org:10.1093/ije/dyx206</u> Soininen, P., Kangas, A. J., Würtz, P., Suna, T. & Ala-Korpela, M. Quantitative Serum Nuclear Magnetic Resonance Metabolomics in Cardiovascular Epidemiology and Genetics. <i>Circulation: Cardiovascular Genetics</i> <b>8</b> , 192-206 (2015). <u>https://doi.org:10.1161/CIRCGENETICS.114.000216</u> Allen, N. E., Sudlow, C., Peakman, T., Collins, R. & Biobank, U. K. UK biobank data: come and get it. <i>Sci Transl Med</i> <b>6</b> , 224ed224 (2014). https://doi.org:10.1126/scitranslmed.3008601
901 902 903 904 905 906 907 908 909 910	48 49 50 51	Munafò, M. R., Tilling, K., Taylor, A. E., Evans, D. M. & Davey Smith, G. Collider scope: when selection bias can substantially influence observed associations. <i>International Journal of</i> <i>Epidemiology</i> <b>47</b> , 226-235 (2018). <u>https://doi.org:10.1093/ije/dyx206</u> Soininen, P., Kangas, A. J., Würtz, P., Suna, T. & Ala-Korpela, M. Quantitative Serum Nuclear Magnetic Resonance Metabolomics in Cardiovascular Epidemiology and Genetics. <i>Circulation: Cardiovascular Genetics</i> <b>8</b> , 192-206 (2015). <u>https://doi.org:10.1161/CIRCGENETICS.114.000216</u> Allen, N. E., Sudlow, C., Peakman, T., Collins, R. & Biobank, U. K. UK biobank data: come and get it. <i>Sci Transl Med</i> <b>6</b> , 224ed224 (2014). <u>https://doi.org:10.1126/scitranslmed.3008601</u> Collins, R. What makes UK Biobank special? <i>Lancet</i> <b>379</b> , 1173-1174 (2012).
901 902 903 904 905 906 907 908 909 910 911	48 49 50 51	Munafò, M. R., Tilling, K., Taylor, A. E., Evans, D. M. & Davey Smith, G. Collider scope: when selection bias can substantially influence observed associations. <i>International Journal of</i> <i>Epidemiology</i> <b>47</b> , 226-235 (2018). <u>https://doi.org:10.1093/ije/dyx206</u> Soininen, P., Kangas, A. J., Würtz, P., Suna, T. & Ala-Korpela, M. Quantitative Serum Nuclear Magnetic Resonance Metabolomics in Cardiovascular Epidemiology and Genetics. <i>Circulation: Cardiovascular Genetics</i> <b>8</b> , 192-206 (2015). <u>https://doi.org:10.1161/CIRCGENETICS.114.000216</u> Allen, N. E., Sudlow, C., Peakman, T., Collins, R. & Biobank, U. K. UK biobank data: come and get it. <i>Sci Transl Med</i> <b>6</b> , 224ed224 (2014). <u>https://doi.org:10.1126/scitranslmed.3008601</u> Collins, R. What makes UK Biobank special? <i>Lancet</i> <b>379</b> , 1173-1174 (2012). https://doi.org:10.1016/S0140-6736(12)60404-8
901 902 903 904 905 906 907 908 909 910 911 912	48 49 50 51 52	<ul> <li>Munafò, M. R., Tilling, K., Taylor, A. E., Evans, D. M. &amp; Davey Smith, G. Collider scope: when selection bias can substantially influence observed associations. <i>International Journal of Epidemiology</i> 47, 226-235 (2018). <a href="https://doi.org:10.1093/ije/dyx206">https://doi.org:10.1093/ije/dyx206</a></li> <li>Soininen, P., Kangas, A. J., Würtz, P., Suna, T. &amp; Ala-Korpela, M. Quantitative Serum Nuclear Magnetic Resonance Metabolomics in Cardiovascular Epidemiology and Genetics. <i>Circulation: Cardiovascular Genetics</i> 8, 192-206 (2015).</li> <li><a href="https://doi.org:10.1161/CIRCGENETICS.114.000216">https://doi.org:10.1161/CIRCGENETICS.114.000216</a></li> <li>Allen, N. E., Sudlow, C., Peakman, T., Collins, R. &amp; Biobank, U. K. UK biobank data: come and get it. <i>Sci Transl Med</i> 6, 224ed224 (2014). <a href="https://doi.org:10.1126/scitranslmed.3008601">https://doi.org:10.1126/scitranslmed.3008601</a></li> <li>Collins, R. What makes UK Biobank special? <i>Lancet</i> 379, 1173-1174 (2012).</li> <li><a href="https://doi.org:10.1016/S0140-6736(12)60404-8">https://doi.org:10.1016/S0140-6736(12)60404-8</a></li> <li>Julkunen, H., Cichonska, A., Slagboom, P. E., Wurtz, P. &amp; Nightingale Health, U. K. B. I.</li> </ul>
901 902 903 904 905 906 907 908 909 910 911 912 913	48 49 50 51 52	Munafò, M. R., Tilling, K., Taylor, A. E., Evans, D. M. & Davey Smith, G. Collider scope: when selection bias can substantially influence observed associations. <i>International Journal of</i> <i>Epidemiology</i> <b>47</b> , 226-235 (2018). <u>https://doi.org:10.1093/ije/dyx206</u> Soininen, P., Kangas, A. J., Würtz, P., Suna, T. & Ala-Korpela, M. Quantitative Serum Nuclear Magnetic Resonance Metabolomics in Cardiovascular Epidemiology and Genetics. <i>Circulation: Cardiovascular Genetics</i> <b>8</b> , 192-206 (2015). <u>https://doi.org:10.1161/CIRCGENETICS.114.000216</u> Allen, N. E., Sudlow, C., Peakman, T., Collins, R. & Biobank, U. K. UK biobank data: come and get it. <i>Sci Transl Med</i> <b>6</b> , 224ed224 (2014). <u>https://doi.org:10.1126/scitranslmed.3008601</u> Collins, R. What makes UK Biobank special? <i>Lancet</i> <b>379</b> , 1173-1174 (2012). <u>https://doi.org:10.1016/S0140-6736(12)60404-8</u> Julkunen, H., Cichonska, A., Slagboom, P. E., Wurtz, P. & Nightingale Health, U. K. B. I. Metabolic biomarker profiling for identification of susceptibility to severe pneumonia and
901 902 903 904 905 906 907 908 909 910 911 912 913 914	48 49 50 51 52	Munafò, M. R., Tilling, K., Taylor, A. E., Evans, D. M. & Davey Smith, G. Collider scope: when selection bias can substantially influence observed associations. <i>International Journal of</i> <i>Epidemiology</i> <b>47</b> , 226-235 (2018). <u>https://doi.org:10.1093/ije/dyx206</u> Soininen, P., Kangas, A. J., Würtz, P., Suna, T. & Ala-Korpela, M. Quantitative Serum Nuclear Magnetic Resonance Metabolomics in Cardiovascular Epidemiology and Genetics. <i>Circulation: Cardiovascular Genetics</i> <b>8</b> , 192-206 (2015). <u>https://doi.org:10.1161/CIRCGENETICS.114.000216</u> Allen, N. E., Sudlow, C., Peakman, T., Collins, R. & Biobank, U. K. UK biobank data: come and get it. <i>Sci Transl Med</i> <b>6</b> , 224ed224 (2014). <u>https://doi.org:10.1126/scitranslmed.3008601</u> Collins, R. What makes UK Biobank special? <i>Lancet</i> <b>379</b> , 1173-1174 (2012). <u>https://doi.org:10.1016/S0140-6736(12)60404-8</u> Julkunen, H., Cichonska, A., Slagboom, P. E., Wurtz, P. & Nightingale Health, U. K. B. I. Metabolic biomarker profiling for identification of susceptibility to severe pneumonia and COVID-19 in the general population. <i>Elife</i> <b>10</b> (2021). https://doi.org:10.7554/eLife.63033
901 902 903 904 905 906 907 908 909 910 911 912 913 914 915	48 49 50 51 52 53	Munafò, M. R., Tilling, K., Taylor, A. E., Evans, D. M. & Davey Smith, G. Collider scope: when selection bias can substantially influence observed associations. <i>International Journal of</i> <i>Epidemiology</i> <b>47</b> , 226-235 (2018). <u>https://doi.org:10.1093/ije/dyx206</u> Soininen, P., Kangas, A. J., Würtz, P., Suna, T. & Ala-Korpela, M. Quantitative Serum Nuclear Magnetic Resonance Metabolomics in Cardiovascular Epidemiology and Genetics. <i>Circulation: Cardiovascular Genetics</i> <b>8</b> , 192-206 (2015). <u>https://doi.org:10.1161/CIRCGENETICS.114.000216</u> Allen, N. E., Sudlow, C., Peakman, T., Collins, R. & Biobank, U. K. UK biobank data: come and get it. <i>Sci Transl Med</i> <b>6</b> , 224ed224 (2014). <u>https://doi.org:10.1126/scitranslmed.3008601</u> Collins, R. What makes UK Biobank special? <i>Lancet</i> <b>379</b> , 1173-1174 (2012). <u>https://doi.org:10.1016/S0140-6736(12)60404-8</u> Julkunen, H., Cichonska, A., Slagboom, P. E., Wurtz, P. & Nightingale Health, U. K. B. I. Metabolic biomarker profiling for identification of susceptibility to severe pneumonia and COVID-19 in the general population. <i>Elife</i> <b>10</b> (2021). <u>https://doi.org:10.7554/eLife.63033</u> Soininen, P., Kangas, A. J., Wurtz, P., Suna, T. & Ala-Korpela, M. Quantitative serum nuclear
901 902 903 904 905 906 907 908 909 910 911 912 913 914 915 916	48 49 50 51 52 53	Munafò, M. R., Tilling, K., Taylor, A. E., Evans, D. M. & Davey Smith, G. Collider scope: when selection bias can substantially influence observed associations. <i>International Journal of</i> <i>Epidemiology</i> <b>47</b> , 226-235 (2018). <u>https://doi.org:10.1093/ije/dyx206</u> Soininen, P., Kangas, A. J., Würtz, P., Suna, T. & Ala-Korpela, M. Quantitative Serum Nuclear Magnetic Resonance Metabolomics in Cardiovascular Epidemiology and Genetics. <i>Circulation: Cardiovascular Genetics</i> <b>8</b> , 192-206 (2015). <u>https://doi.org:10.1161/CIRCGENETICS.114.000216</u> Allen, N. E., Sudlow, C., Peakman, T., Collins, R. & Biobank, U. K. UK biobank data: come and get it. <i>Sci Transl Med</i> <b>6</b> , 224ed224 (2014). <u>https://doi.org:10.1126/scitranslmed.3008601</u> Collins, R. What makes UK Biobank special? <i>Lancet</i> <b>379</b> , 1173-1174 (2012). <u>https://doi.org:10.1016/S0140-6736(12)60404-8</u> Julkunen, H., Cichonska, A., Slagboom, P. E., Wurtz, P. & Nightingale Health, U. K. B. I. Metabolic biomarker profiling for identification of susceptibility to severe pneumonia and COVID-19 in the general population. <i>Elife</i> <b>10</b> (2021). <u>https://doi.org:10.7554/eLife.63033</u> Soininen, P., Kangas, A. J., Wurtz, P., Suna, T. & Ala-Korpela, M. Quantitative serum nuclear magnetic resonance metabolomics in cardiovascular epidemiology and genetics. <i>Circ</i>
901 902 903 904 905 906 907 908 909 910 911 912 913 914 915 916 917	48 49 50 51 52 53	Munafò, M. R., Tilling, K., Taylor, A. E., Evans, D. M. & Davey Smith, G. Collider scope: when selection bias can substantially influence observed associations. <i>International Journal of Epidemiology</i> <b>47</b> , 226-235 (2018). <a href="https://doi.org:10.1093/ije/dyx206">https://doi.org:10.1093/ije/dyx206</a> Soininen, P., Kangas, A. J., Würtz, P., Suna, T. & Ala-Korpela, M. Quantitative Serum Nuclear Magnetic Resonance Metabolomics in Cardiovascular Epidemiology and Genetics. <i>Circulation: Cardiovascular Genetics</i> <b>8</b> , 192-206 (2015). <a href="https://doi.org:10.1161/CIRCGENETICS.114.000216">https://doi.org:10.1161/CIRCGENETICS.114.000216</a> Allen, N. E., Sudlow, C., Peakman, T., Collins, R. & Biobank, U. K. UK biobank data: come and get it. <i>Sci Transl Med</i> <b>6</b> , 224ed224 (2014). <a href="https://doi.org:10.1126/scitranslmed.3008601">https://doi.org:10.1126/scitranslmed.3008601</a> Collins, R. What makes UK Biobank special? <i>Lancet</i> <b>379</b> , 1173-1174 (2012). <a href="https://doi.org:10.1016/S0140-6736(12)60404-8">https://doi.org:10.1016/S0140-6736(12)60404-8</a> Julkunen, H., Cichonska, A., Slagboom, P. E., Wurtz, P. & Nightingale Health, U. K. B. I. Metabolic biomarker profiling for identification of susceptibility to severe pneumonia and COVID-19 in the general population. <i>Elife</i> <b>10</b> (2021). <a href="https://doi.org:10.7554/eLife.63033">https://doi.org:10.7554/eLife.63033</a> Soininen, P., Kangas, A. J., Wurtz, P., Suna, T. & Ala-Korpela, M. Quantitative serum nuclear magnetic resonance metabolomics in cardiovascular epidemiology and genetics. <i>Circ Cardiovasc Genet</i> <b>8</b> , 192-206 (2015). <a href="https://doi.org:10.1161/CIRCGENETICS.114.000216">https://doi.org:10.1161/CIRCGENETICS.114.000216</a>
901 902 903 904 905 906 907 908 909 910 911 912 913 914 915 916 917 918	48 49 50 51 52 53 54	Munafò, M. R., Tilling, K., Taylor, A. E., Evans, D. M. & Davey Smith, G. Collider scope: when selection bias can substantially influence observed associations. <i>International Journal of</i> <i>Epidemiology</i> <b>47</b> , 226-235 (2018). https://doi.org:10.1093/ije/dyx206 Soininen, P., Kangas, A. J., Würtz, P., Suna, T. & Ala-Korpela, M. Quantitative Serum Nuclear Magnetic Resonance Metabolomics in Cardiovascular Epidemiology and Genetics. <i>Circulation: Cardiovascular Genetics</i> <b>8</b> , 192-206 (2015). https://doi.org:10.1161/CIRCGENETICS.114.000216 Allen, N. E., Sudlow, C., Peakman, T., Collins, R. & Biobank, U. K. UK biobank data: come and get it. <i>Sci Transl Med</i> <b>6</b> , 224ed224 (2014). https://doi.org:10.1126/scitranslmed.3008601 Collins, R. What makes UK Biobank special? <i>Lancet</i> <b>379</b> , 1173-1174 (2012). https://doi.org:10.1016/S0140-6736(12)60404-8 Julkunen, H., Cichonska, A., Slagboom, P. E., Wurtz, P. & Nightingale Health, U. K. B. I. Metabolic biomarker profiling for identification of susceptibility to severe pneumonia and COVID-19 in the general population. <i>Elife</i> <b>10</b> (2021). https://doi.org:10.7554/eLife.63033 Soininen, P., Kangas, A. J., Wurtz, P., Suna, T. & Ala-Korpela, M. Quantitative serum nuclear magnetic resonance metabolomics in cardiovascular epidemiology and genetics. <i>Circ</i> <i>Cardiovasc Genet</i> <b>8</b> , 192-206 (2015). https://doi.org:10.1161/CIRCGENETICS.114.000216 Daniel Fry, R. A., Stewart Moffat, Mark Gordon & Parmesher Singh. <i>UK Biobank Biomarker</i>
901 902 903 904 905 906 907 908 909 910 911 912 913 914 915 916 917 918 919	48 49 50 51 52 53 54	<ul> <li>Munafò, M. R., Tilling, K., Taylor, A. E., Evans, D. M. &amp; Davey Smith, G. Collider scope: when selection bias can substantially influence observed associations. <i>International Journal of Epidemiology</i> <b>47</b>, 226-235 (2018). <a href="https://doi.org:10.1093/ije/dyx206">https://doi.org:10.1093/ije/dyx206</a></li> <li>Soininen, P., Kangas, A. J., Würtz, P., Suna, T. &amp; Ala-Korpela, M. Quantitative Serum Nuclear Magnetic Resonance Metabolomics in Cardiovascular Epidemiology and Genetics. <i>Circulation: Cardiovascular Genetics</i> <b>8</b>, 192-206 (2015).</li> <li><a href="https://doi.org:10.1161/CIRCGENETICS.114.000216">https://doi.org:10.1161/CIRCGENETICS.114.000216</a></li> <li>Allen, N. E., Sudlow, C., Peakman, T., Collins, R. &amp; Biobank, U. K. UK biobank data: come and get it. <i>Sci Transl Med</i> <b>6</b>, 224ed224 (2014). <a href="https://doi.org:10.1126/scitranslmed.3008601">https://doi.org:10.1161/CIRCGENETICS.114.000216</a></li> <li>Allen, N. E., Sudlow, C., Peakman, T., Collins, R. &amp; Biobank, U. K. UK biobank data: come and get it. <i>Sci Transl Med</i> <b>6</b>, 224ed224 (2014). <a href="https://doi.org:10.1126/scitranslmed.3008601">https://doi.org:10.1126/scitranslmed.3008601</a></li> <li>Collins, R. What makes UK Biobank special? <i>Lancet</i> <b>379</b>, 1173-1174 (2012). <a href="https://doi.org:10.1016/S0140-6736(12)60404-8">https://doi.org:10.1016/S0140-6736(12)60404-8</a></li> <li>Julkunen, H., Cichonska, A., Slagboom, P. E., Wurtz, P. &amp; Nightingale Health, U. K. B. I. Metabolic biomarker profiling for identification of susceptibility to severe pneumonia and COVID-19 in the general population. <i>Elife</i> <b>10</b> (2021). <a href="https://doi.org:10.7554/eLife.63033">https://doi.org:10.7554/eLife.63033</a></li> <li>Soininen, P., Kangas, A. J., Wurtz, P., Suna, T. &amp; Ala-Korpela, M. Quantitative serum nuclear magnetic resonance metabolomics in cardiovascular epidemiology and genetics. <i>Circ Cardiovasc Genet</i> <b>8</b>, 192-206 (2015). <a href="https://doi.org:10.1161/CIRCGENETICS.114.000216">https://doi.org:10.1161/CIRCGENETICS.114.000216</a>&lt;</li></ul>
901 902 903 904 905 906 907 908 909 910 911 912 913 914 915 916 917 918 919 920	48 49 50 51 52 53 54	Munafò, M. R., Tilling, K., Taylor, A. E., Evans, D. M. & Davey Smith, G. Collider scope: when selection bias can substantially influence observed associations. <i>International Journal of</i> <i>Epidemiology</i> <b>47</b> , 226-235 (2018). <u>https://doi.org:10.1093/ije/dyx206</u> Soininen, P., Kangas, A. J., Würtz, P., Suna, T. & Ala-Korpela, M. Quantitative Serum Nuclear Magnetic Resonance Metabolomics in Cardiovascular Epidemiology and Genetics. <i>Circulation: Cardiovascular Genetics</i> <b>8</b> , 192-206 (2015). <u>https://doi.org:10.1161/CIRCGENETICS.114.000216</u> Allen, N. E., Sudlow, C., Peakman, T., Collins, R. & Biobank, U. K. UK biobank data: come and get it. <i>Sci Transl Med</i> <b>6</b> , 224ed224 (2014). <u>https://doi.org:10.1126/scitranslmed.3008601</u> Collins, R. What makes UK Biobank special? <i>Lancet</i> <b>379</b> , 1173-1174 (2012). <u>https://doi.org:10.1016/S0140-6736(12)60404-8</u> Julkunen, H., Cichonska, A., Slagboom, P. E., Wurtz, P. & Nightingale Health, U. K. B. I. Metabolic biomarker profiling for identification of susceptibility to severe pneumonia and COVID-19 in the general population. <i>Elife</i> <b>10</b> (2021). <u>https://doi.org:10.7554/eLife.63033</u> Soininen, P., Kangas, A. J., Wurtz, P., Suna, T. & Ala-Korpela, M. Quantitative serum nuclear magnetic resonance metabolomics in cardiovascular epidemiology and genetics. <i>Circ</i> <i>Cardiovasc Genet</i> <b>8</b> , 192-206 (2015). <u>https://doi.org:10.1161/CIRCGENETICS.114.000216</u> Daniel Fry, R. A., Stewart Moffat, Mark Gordon & Parmesher Singh. <i>UK Biobank Biomarker</i> <i>Project Companion Document to Accompany Serum Biomarker Data</i> , < <u>https://biobank.ndph.ox.ac.uk/showcase/showcase/docs/serum biochemistry.pdf</u> > (2019).
901 902 903 904 905 906 907 908 909 910 911 912 913 914 915 916 917 918 919 920 921	48 49 50 51 52 53 54 55	Munafò, M. R., Tilling, K., Taylor, A. E., Evans, D. M. & Davey Smith, G. Collider scope: when selection bias can substantially influence observed associations. <i>International Journal of Epidemiology</i> <b>47</b> , 226-235 (2018). https://doi.org:10.1093/ije/dyx206 Soininen, P., Kangas, A. J., Würtz, P., Suna, T. & Ala-Korpela, M. Quantitative Serum Nuclear Magnetic Resonance Metabolomics in Cardiovascular Epidemiology and Genetics. <i>Circulation: Cardiovascular Genetics</i> <b>8</b> , 192-206 (2015). https://doi.org:10.1161/CIRCGENETICS.114.000216 Allen, N. E., Sudlow, C., Peakman, T., Collins, R. & Biobank, U. K. UK biobank data: come and get it. <i>Sci Transl Med</i> <b>6</b> , 224ed224 (2014). https://doi.org:10.1126/scitranslmed.3008601 Collins, R. What makes UK Biobank special? <i>Lancet</i> <b>379</b> , 1173-1174 (2012). https://doi.org:10.1016/S0140-6736(12)60404-8 Julkunen, H., Cichonska, A., Slagboom, P. E., Wurtz, P. & Nightingale Health, U. K. B. I. Metabolic biomarker profiling for identification of susceptibility to severe pneumonia and COVID-19 in the general population. <i>Elife</i> <b>10</b> (2021). https://doi.org:10.7554/eLife.63033 Soininen, P., Kangas, A. J., Wurtz, P., Suna, T. & Ala-Korpela, M. Quantitative serum nuclear magnetic resonance metabolomics in cardiovascular epidemiology and genetics. <i>Circ</i> <i>Cardiovasc Genet</i> <b>8</b> , 192-206 (2015). https://doi.org:10.1161/CIRCGENETICS.114.000216 Daniel Fry, R. A., Stewart Moffat, Mark Gordon & Parmesher Singh. <i>UK Biobank Biomarker</i> <i>Project Companion Document to Accompany Serum Biomarker Data</i> , <https: biobank.ndph.ox.ac.uk="" biochemistry.pdf="" docs="" serum="" showcase=""> (2019). Bycroft, C. <i>et al.</i> The UK Biobank resource with deep phenotyping and genomic data. <i>Nature</i></https:>

923 56 Howie, B., Marchini, J. & Stephens, M. Genotype imputation with thousands of genomes. G3 (Bethesda) 1, 457-470 (2011). https://doi.org:10.1534/g3.111.001198 924 Huang, J. et al. Improved imputation of low-frequency and rare variants using the UK10K 925 57 926 haplotype reference panel. Nat Commun 6, 8111 (2015). 927 https://doi.org:10.1038/ncomms9111 928 58 Mitchell, R., Hemani, G., Dudding, T., Corbin, L., Harrison, S., Paternoster, L. UK Biobank 929 Genetic Data: MRC-IEU Quality Control, version 2 - Datasets - data.bris. data.bris. (2018). 930 https://doi.org:10.5523/bris.1ovaau5sxunp2cv8rcy88688v 931 59 Mitchell R, E. B., Raistrick CA, Paternoster L, Hemani G, Gaunt TR. MRC IEU UK Biobank 932 GWAS pipeline version 2. (2019). https://doi.org:10.5523/bris.pnoat8cxo0u52p6ynfaekeigi 933 60 Loh, P. R. et al. Efficient Bayesian mixed-model analysis increases association power in large 934 cohorts. Nat Genet 47, 284-290 (2015). https://doi.org:10.1038/ng.3190 935 Kettunen, J. et al. Genome-wide study for circulating metabolites identifies 62 loci and 61 936 reveals novel systemic effects of LPA. Nat Commun 7, 11122 (2016). 937 https://doi.org:10.1038/ncomms11122 938 Bruna, G., Mary, S., Debbie, A. L., John, W. L. & George Davey, S. Indicators of socioeconomic 62 939 position (part 1). Journal of Epidemiology and Community Health 60, 7 (2006). 940 https://doi.org:10.1136/jech.2004.023531 941 63 Harrell, J. F. E. & SpringerLink. Regression Modeling Strategies : With Applications to Linear 942 Models, Logistic and Ordinal Regression, and Survival Analysis. 1 online resource (XXV, 582 p. 943 157 illus., 553 illus. in color.) (2015). 944 64 Lawlor, D. A. Commentary: Two-sample Mendelian randomization: opportunities and 945 challenges. Int J Epidemiol 45, 908-915 (2016). https://doi.org:10.1093/ije/dyw127 946 Day, F. R. et al. Genomic analyses identify hundreds of variants associated with age at 65 947 menarche and support a role for puberty timing in cancer risk. Nat Genet 49, 834-841 948 (2017). https://doi.org:10.1038/ng.3841 949 Perry, J. R. et al. Parent-of-origin-specific allelic associations among 106 genomic loci for age 66 950 at menarche. Nature 514, 92-97 (2014). https://doi.org:10.1038/nature13545 951 67 Mathieson, I. et al. Genome-wide analysis identifies genetic effects on reproductive success 952 and ongoing natural selection at the <em>FADS</em> locus. *bioRxiv*, 953 2020.2005.2019.104455 (2020). https://doi.org:10.1101/2020.05.19.104455 954 Day, F. R. et al. Large-scale genomic analyses link reproductive aging to hypothalamic 68 955 signaling, breast cancer susceptibility and BRCA1-mediated DNA repair. Nat Genet 47, 1294-956 1303 (2015). https://doi.org:10.1038/ng.3412 957 69 Locke, A. E. et al. Genetic studies of body mass index yield new insights for obesity biology. 958 Nature 518, 197-206 (2015). https://doi.org:10.1038/nature14177 959 70 Howe, L. J. et al. Within-sibship GWAS improve estimates of direct genetic effects. bioRxiv, 960 2021.2003.2005.433935 (2021). https://doi.org:10.1101/2021.03.05.433935 961 71 Davies, N. M. et al. Within family Mendelian randomization studies. Hum Mol Genet 28, 962 R170-R179 (2019). https://doi.org:10.1093/hmg/ddz204 963 72 Morris, T. T., Davies, N. M., Hemani, G. & Smith, G. D. Population phenomena inflate genetic 964 associations of complex social traits. Sci Adv 6, eaay0328 (2020). https://doi.org:10.1126/sciadv.aav0328 965 Sanderson, E., Richardson, T. G., Hemani, G. & Davey Smith, G. The use of negative control 966 73 967 outcomes in Mendelian randomization to detect potential population stratification. Int J Epidemiol (2021). https://doi.org:10.1093/ije/dyaa288 968 969 74 Zheng, J. et al. Recent Developments in Mendelian Randomization Studies. Curr Epidemiol 970 Rep 4, 330-345 (2017). https://doi.org:10.1007/s40471-017-0128-6 971

#### Main tables and figures

Contents page

Figure 1	Infographic summarising the different approaches taken to
	assess associations between reproductive traits and
	metabolites
Figure 2A	Multivariable regression and Mendelian randomization
	estimates for the associations between older age at menarche
	and metabolic measures.
	Results are presented as standard unit changes in metabolic measure per 1
	year increase in age at menarche. Circles denote point estimates and
	indicate p-value < $0.00093$ (closed circle) or $\geq 0.00093$ (open circles).
	models were adjusted for age at recruitment, body size at age 10 and
	education. Mendelian randomization models were estimated using the
	inverse variance weighted method. Abbreviations for Figures 2A-C and 4 are
	given in 'Abbreviations' at the end of the manuscript.
Figure 2B	Multivariable regression and Mendelian randomization
	estimates for the associations between higher parity and
	metabolic measures.
	Mendelian randomization estimates for the associations
	between reproductive traits (i.e. older age at menarche, higher
	parity, and older age at natural menopause) and metabolic
	measures
	Results are presented as standard unit changes in metabolic measure per 1
	additional birth. Circles denote point estimates and indicate p-value <
	0.00093 (closed circle) or $\geq$ 0.00093 (open circles). Horizontal bars denote
	age at recruitment, body size at age 10 and education. Mendelian
	randomization models were estimated using the inverse variance weighted
	method. Abbreviations for Figures 2A-C and 4 are given in 'Abbreviations' at
	the end of the manuscript.
Figure 2C	Multivariable regression and Mendelian randomization
	estimates for the associations between older age at natural
	menopause and metabolic measures.
	Results are presented as standard unit changes in metabolic measure per 1
	year increase in age at natural menopause. Circles denote point estimates
	and indicate p-value < $0.00093$ (closed circle) or $\ge 0.00093$ (open circles).
	models were adjusted for age at recruitment. body size at age 10 and
	Page 1 of 11

n	nedRxiv preprint doi: https://doi.org/10.1101/20 (which was not certified by peer review) is It is made av	022.04.17.22273947; this version posted May 5, 2023. The copyright holder for this preprint the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. <i>v</i> ailable under a CC-BY-NC-ND 4.0 International license .
		education. Mendelian randomization models were estimated using the
		inverse variance weighted method. Abbreviations for Figures 2A-C and 4 are
		given in 'Abbreviations' at the end of the manuscript.
	Figure 3	Mendelian randomization estimates for the relation between
		reproductive traits and metabolic measures among females
		assayed using NMR metabolomics (black) or clinical chemistry
		<u>methods (pink)</u>
		Results are presented as standard unit changes in metabolic measure per 1
		year increase in age at menarche, 1 additional birth, or 1 year increase in
		age at natural menopause. Circles denote point estimates and indicate p-
		value < 0.00093 (closed circle) or $\ge$ 0.00093 (open circles). Horizontal bars
		denote 95% confidence intervals.
	Figure 4	Multivariable regression estimates for the associations of parity
		(women) or number of children (men) with metabolic measures:
		negative control analyses
		Results are presented as standard unit changes in metabolic measure per 1
		additional birth/child. Circles denote point estimates and indicate p-value <
		0.00093 (closed circle) or ≥ 0.00093 (open circles). Horizontal bars denote
		95% confidence intervals. Multivariable regression models were adjusted for
		age at recruitment, body size at age 10 and education. Abbreviations for
		Figures 2A, 2B and 4 are given in 'Abbreviations'
	Table 1	Distribution of characteristics of UK Biobank participants with
		NMR metabolomics data
	Summary box	Summary of key findings

#### Fig 1. Overview of study design: key assumptions and biases



The figure illustrates key assumptions and sources of bias for each method (and differences across methods) in the context of our study. An exhaustive review of assumptions/biases for each method is outside the scope of this work. However, we acknowledge that there are other potential sources of biases that could affect findings such as selection bias related to the low response in UKB.

**Figure 2A**. Multivariable regression and Mendelian randomization estimates for the associations between older age at menarche and metabolic measures.

	Amino acids		Fatty acids
Ala		DHA	<u> </u>
Gln	<u> </u>	LA	
Ghy	· · · · · · · · · · · · · · · · · · ·	MUFA	<u>+</u>
Giy		Omega_3	
HIS		Omega_6	
lle		SFA	
Leu		Total FA	<u> </u>
Phe		Unsaturation	<del></del>
Tyr			Cholesterol
Val		Clinical LDL C	<u> </u>
	Chreathais related metabolitos	HDL_C	
	Giveolysis related metabolites	LDL_C	
Citrate		Total_C	
Glucose		VLDL_C	
Lactate			Cholesteryl esters
Pyruvate		HDL_CE	
	Katana hadica	LDL_CE	
	Ketone bodies	Total_CE	
Acetate		VLDL_CE	
Acetoacetate			Free cholesterol
Acetone		HDL_FC	
bOHbutyrate		LDL_FC	<b>→</b>
	Eluid belence	Total_FC	
		VLDL_FC	
Albumin			Phospholipids
Creatinine		HDL_PL	
	Inflammation	LDL_PL	
Chur A		Total_PL	
GIYCA		VLDL_PL	
	Apolipoproteins		Triglycerides
ApoA1		HDL_TG	
ApoB		LDL_TG	
	Particle concentration	VLDL_10	
HDL_P			Other lipids
LDL_P		Cholines	
Total P		Phosphatidylc	
	<u> </u>	Phosphoglyc	
VEDE_I		Springornyeins	
	Particle size		lotal lipids
HDL_size		HDL_L	
LDL_size		LUL_L Total L	
VLDL_size	<u> </u>	VLDL_L	<u> </u>
	-0.10 -0.05 0.00 0.05 0.10 1-SD increment in metabolite per year increase in age at menarche		-0.10 -0.05 0.00 0.05 0.10 1-SD increment in metabolite per year increase in age at menarche
	· MV	· MIK	

#### Figure 2B. Multivariable regression and Mendelian randomization estimates for the associations between

higher parity and metabolic measures.



# Figure 2C. Multivariable regression and Mendelian randomization estimates for the associations between older

age at natural menopause and metabolic measures.







**Figure 4**. Multivariable regression estimates for the associations of parity (women) or number of children (men) with metabolic measures: negative control analyses Models adjusted for age at baseline, education, and body composition at age 10.



# **Table 1**. Distribution of characteristics of UK Biobank participants (females only) with NMR metabolomics data

Age when attended assessment centre, mean (sd)       56.4 (8.0)         Age in 5-y groups, n (%)       6623 (10.1)         40-       6623 (10.1)         45-       8781 (13.4)         50-       10378 (15.8)         55-       12299 (18.7)         60-       16089 (24.5)         65-       11529 (17.5)         Ethnic background, n (%)       62063 (94.8)         Mixed       420 (0.6)         Asian       1069 (16.5)         Black       1059 (16.9)         Others       609 (0.9)         Qualifications, n (%)       200 (3)         O level or CSEs or other       25619 (39.4)         A level       7664 (1.7)         College/ university       20749 (31.9)         Townsend deprivation index at recruitment, mean (sd)       -14 (3.0)         Comparative body size at age 10, n (%)       271 (5.2)         Alcohal intak frequency., n (%)       271 (5.2)         Daily or almost daily       10516 (16.0)         Three or four times a week       1372 (20.9)         Once or twice a week       1372 (20.9)         Once or twice a week       1686 (20.4)         Once or twice a week       1686 (6.9)         Special occasions only       9630		N=65699
Age in 5-y groups, n (%)       6623 (10.1)         40-       6623 (10.1)         45-       8781 (13.4)         50-       10378 (15.8)         55-       12299 (18.7)         60-       16089 (24.5)         65-       11529 (17.5)         Ethnic background, n (%)       62063 (94.8)         Mixed       420 (0.6)         Asian       1069 (1.6)         Black       1059 (1.6)         Chinese       220 (0.3)         Qualifications, n (%)       0         Qualifications, n (%)       0         None of the above       1059 (1.6)         O level or CSEs or other       25619 (39.4)         A level       7626 (11.7)         College/ university       20749 (31.9)         Townsend deprivation index at recruitment, mean (sd)       -1.4 (3.0)         College/ university       20749 (31.8)         Townsend deprivation index at recruitment, mean (sd)       2.7.1 (5.2)         Alevel       7626 (11.7)         College/ university       20749 (31.8)         Townsend deprivation index at recruitment, mean (sd)       2.7.1 (5.2)         Alevel       72.7 (5.2)         Alevel       72.7 (5.2)         Dotto tintinas	Age when attended assessment centre, mean (sd)	56.4 (8.0)
40-         6623 (10.1)           45-         8781 (13.4)           50-         10376 (15.8)           55-         12299 (18.7)           60-         16089 (24.5)           65-         11529 (17.5)           Ethnic background, n (%)         White           White         62063 (94.8)           Mixed         420 (0.6)           Saian         1069 (1.6)           Black         1059 (1.6)           Chinese         220 (0.3)           Others         609 (0.9)           Qualifications, n (%)         White           None of the above         10955 (16.9)           O level or CSEs or other         25619 (39.4)           A level         7626 (11.7)           College/ university         20749 (31.9)           Townsend deprivation index at recruitment, mean (sd)         -1.4 (3.0)           Comparative body size at age 10, n (%)         27.1 (5.2)           Average         32767 (50.7)           Thinner         20416 (31.6)           Plumper         11312 (20.9)           Once or twice a week         13712 (20.9)           Once or twice a week         13712 (20.9)           Once or twice a week         13872 (25.7)	Age in 5-y groups, n (%)	
45.       878 (13.4)         50.       1078 (15.8)         55.       12299 (18.7)         60.       16089 (24.5)         65.       11529 (17.5)         Ethnic background, n (%)       2000 (34.8)         Mixed       420 (0.6)         Asian       1069 (1.6)         Black       1059 (1.6)         Chinese       220 (0.3)         Others       609 (0.9)         Qualifications, n (%)       10955 (16.9)         None of the above       10955 (16.9)         O level or CSEs or other       25619 (39.4)         A level       7626 (11.7)         College/ university       20749 (31.8)         Townsend depivation index at recruitment, mean (sd)       -1.4 (3.0)         Comparative body size at age 10, n (%)       2761 (51.6)         Average       32767 (50.7)         Thinner       20416 (31.6)         Plumper       11435 (17.7)         Body mass index (BMI), mean (sd)       27.1 (5.2)         Alcohol intake frequency n (%)       20160 (31.6)         Daily or almost daily       10516 (16.0)         Three or four times a week       13712 (20.9)         Once or twice a week       16872 (25.7)         On	40-	6623 (10.1)
50-         10378 (15.8)           55-         1299 (18.7)           60-         16089 (24.5)           65-         11529 (17.5)           Ethnic background, n (%)         20063 (94.8)           Mixed         420 (0.6)           Asian         1069 (1.6)           Black         1059 (1.6)           Chinese         220 (0.3)           Quilifications, n (%)         2000 (0.9)           None of the above         10955 (16.9)           O level or CSEs or other         25619 (39.4)           A level         7626 (11.7)           College/ university         20749 (31.9)           Townsend deprivation index at recruitment, mean (sd)         -1.4 (3.0)           Comparative body size at age 10, n (%)         27.1 (5.2)           Average         32767 (50.7)           Thinner         20416 (31.6)           Plumper         11435 (17.7)           Body mass index (BMI), mean (sd)         2.7.1 (5.2)           Alcohol intake frequency., n (%)         20140 (31.6)           Daily or almost daily         10516 (16.0)           Three or four times a week         13712 (20.9)           Once ot twice a week         6855 (13.2)           One to three times a month         865	45-	8781 (13.4)
55-       12299 (18.7)         60-       16089 (24.5)         65-       11529 (17.5)         Ethnic background, n (%)          White       62063 (94.8)         Mixed       420 (0.6)         Saian       1069 (1.6)         Black       1059 (1.6)         Chinese       220 (0.3)         Others       609 (0.9)         Qualifications, n (%)          None of the above       10955 (16.9)         O level or CSEs or other       25619 (39.4)         A level       7626 (11.7)         College/ university       20749 (31.9)         Townsend deprivation index at recruitment, mean (sd)       -1.4 (3.0)         Comparative body size at age 10, n (%)          Average       32767 (50.7)         Thinner       20416 (31.6)         Plumper       11435 (17.7)         Body mass index (BM), mean (sd)       27.1 (5.2)         Alcoho intake frequency., n (%)          Daily or almost daily       10516 (16.0)         Three or four times a week       13712 (20.9)         Once or twice a week       16872 (25.7)         One to three times a month       8655 (13.2)         Special occasions only </td <td>50-</td> <td>10378 (15.8)</td>	50-	10378 (15.8)
60-         16089 (24.5)           65-         11529 (17.5)           Ethnic background, n (%)         62063 (94.8)           Mixed         420 (0.6)           Asian         1069 (1.6)           Black         1059 (1.6)           Chinese         220 (0.3)           Others         609 (0.9)           Qualifications, n (%)         10955 (16.9)           None of the above         10955 (16.9)           O level or CSEs or other         25619 (39.4)           A level         7626 (11.7)           College/ university         20749 (31.9)           Townsend deprivation index at recruitment, mean (sd)         -1.4 (3.0)           Comparative body size at age 10, n (%)         Average           Average         32767 (50.7)           Thinner         20416 (31.6)           Plumper         11435 (17.7)           Body mass index (BMI), mean (sd)         27.1 (5.2)           Alcohal intake frequency, n (%)         20416 (31.6)           Daily or almost daily         10516 (16.0)           Three or four times a week         13712 (20.9)           Once or twice a week         16872 (25.7)           Ont three times a month         8655 (13.2)           Special occasions only	55-	12299 (18.7)
65-       11529 (17.5)         Ethnic background, n (%)          White       62063 (94.8)         Mixed       420 (0.6)         Asian       1069 (1.6)         Black       1059 (1.6)         Chinese       220 (0.3)         Others       609 (0.9)         Qualifications, n (%)          None of the above       10955 (16.9)         O level or CSEs or other       25619 (39.4)         A level       7626 (11.7)         College/ university       20749 (31.9)         Townsend deprivation index at recruitment, mean (sd)       -1.4 (3.0)         Comparative body size at age 10, n (%)       32767 (50.7)         Thinner       20416 (31.6)         Plumper       11435 (17.7)         Body mass index (BM), mean (sd)       27.1 (5.2)         Alcohol intake frequency., n (%)       27.1 (5.2)         Once or twice a week       10516 (16.0)         Three or four times a week       13712 (20.9)         Once or twice a week       16872 (25.7)         Once or twice a week       16872 (25.9)         Special occasions only       9630 (14.7)         Never       38915 (59.5)         Previous       20609 (31.5)      <	60-	16089 (24.5)
Ethnic background, n (%)         White       62063 (94.8)         Mixed       420 (0.6)         Asian       1068 (1.6)         Black       1059 (1.6)         Chinese       220 (0.3)         Others       609 (0.9)         Qualifications, n (%)       10955 (16.9)         O level or CSEs or other       25619 (39.4)         A level       7626 (11.7)         College/ university       20749 (31.9)         Townsend deprivation index at recruitment, mean (sd)       -1.4 (3.0)         Comparative body size at age 10, n (%)       27.1 (5.2)         Average       32767 (50.7)         Thinner       204416 (31.6)         Plumper       11435 (17.7)         Body mass index (BMI), mean (sd)       27.1 (5.2)         Alcohol intake frequency., n (%)       20150 (16.0)         Thiner       204416 (31.6)         Plumper       13712 (20.9)         Once or twice a week       16872 (25.7)         One to twice a week       16872 (25.7)         One to twice a week       16872 (25.7)         One to twice a week       16852 (13.2)         Special occasions only       9630 (14.7)         Never       38915 (59.5)         Prev	65-	11529 (17.5)
White         62063 (94.8)           Mixed         420 (0.6)           Asian         1069 (1.6)           Black         1059 (1.6)           Chinese         220 (0.3)           Others         609 (0.9)           Qualifications, n (%)         10955 (16.9)           None of the above         10955 (16.9)           O level or CSEs or other         25619 (39.4)           A level         7626 (11.7)           College/ university         20749 (31.9)           Townsend deprivation index at recruitment, mean (sd)         -1.4 (3.0)           Comparative body size at age 10, n (%)         Average           Average         32767 (50.7)           Thinner         20416 (31.6)           Plumper         11435 (17.7)           Body mass index (BMI), mean (sd)         27.1 (5.2)           Alcohol intake frequency n (%)         2010 of almost daily           Daily or almost daily         10516 (16.0)           Drever         6186 (9.4)           Special occasions only         9630 (14.7)           Never         38915 (59.5)           Sprevious         20609 (31.5)           Current         5834 (8.9)           Age when periods started (menarche), mean (sd)         13.0	Ethnic background, n (%)	
Mixed         420 (0.6)           Asian         1069 (1.6)           Black         1059 (1.6)           Chinese         220 (0.3)           Others         609 (0.9)           Qualifications, n (%)         10955 (16.9)           O level or CSEs or other         25619 (39.4)           A level         7626 (11.7)           College/ university         20749 (31.9)           Townsend deprivation index at recruitment, mean (sd)         -1.4 (3.0)           Comparative body size at age 10, n (%)         27416 (31.6)           Average         32767 (50.7)           Thinner         20416 (31.6)           Plumper         11435 (17.7)           Body mass index (BMI), mean (sd)         27.1 (5.2)           Alcohi Intake frequency., n (%)         20416 (31.6)           Daily or almost daily         10516 (16.0)           Three or four times a week         13712 (20.9)           Once or twice a week         13712 (20.9)           Once or twice a week         16872 (25.7)           One to three times a month         8655 (13.2)           Special occasions only         9630 (14.7)           Never         38915 (59.5)           Previous         20609 (31.5)           Current	White	62063 (94.8)
Asian       1069 (1.6)         Black       1059 (1.6)         Chinese       220 (0.3)         Qualifications, n (%)       609 (0.9)         None of the above       10955 (16.9)         O level or CSEs or other       25619 (39.4)         A level       7626 (11.7)         College/ university       20749 (31.9)         Townsend deprivation index at recruitment, mean (sd)       -1.4 (3.0)         Comparative body size at age 10, n (%)       2714 (31.6)         Average       32767 (50.7)         Thinner       20416 (31.6)         Plumper       11435 (17.7)         Body mass index (BMI), mean (sd)       27.1 (5.2)         Alcohol intake frequency., n (%)       27.1 (5.2)         Daily or almost daily       10516 (16.0)         Three or four times a week       13712 (20.9)         Once or twice a week       18872 (25.7)         One to three times a month       8655 (13.2)         Special occasions only       9630 (14.7)         Never       6186 (9.4)         Smoking status, n (%)       31.0 (1.6)         Categories of age at menarche, n (%)       13.0 (1.6)         Categories of age at menarche, n (%)       13.0 (1.6)         Categories of age at menarche, n (%) </td <td>Mixed</td> <td>420 (0.6)</td>	Mixed	420 (0.6)
Black         1059 (1.6)           Chinese         220 (0.3)           Others         609 (0.9)           Qualifications, n (%)            None of the above         10955 (16.9)           O level or CSEs or other         25619 (39.4)           A level         7626 (11.7)           College/ university         20749 (31.9)           Townsend deprivation index at recruitment, mean (sd)         -1.4 (3.0)           Comparative body size at age 10, n (%)         20416 (31.6)           Average         32767 (50.7)           Thinner         20416 (31.6)           Plumper         11435 (17.7)           Body mass index (BMI), mean (sd)         27.1 (5.2)           Acchol intake frequency., n (%)         20516 (16.0)           Three or four times a week         13512 (20.9)           Once or twice a week         18872 (25.7)           One to three times a month         8655 (13.2)           Special occasions only         9630 (14.7)           Never         6186 (9.4)           Smoking status, n (%)         33915 (59.5)           Previous         20609 (31.5)           Current         5834 (8.9)           Age when periods started (meanche), mean (sd)         13.0 (1.6)	Asian	1069 (1.6)
Chinese         220 (0.3)           Others         609 (0.9)           Qualifications, n (%)         609 (0.9)           None of the above         10955 (16.9)           O level or CSEs or other         25619 (39.4)           A level         7626 (11.7)           College/ university         20749 (31.9)           Townsend deprivation index at recruitment, mean (sd)         -1.4 (3.0)           Comparative body size at age 10, n (%)         4           Average         32767 (50.7)           Thinner         20416 (31.6)           Plumper         11435 (17.7)           Body mass index (BMI), mean (sd)         27.1 (5.2)           Alcohol intake frequency., n (%)         27.1 (5.2)           Daily or almost daily         10516 (16.0)           Three or four times a week         13712 (20.9)           Once or twice a week         16872 (25.7)           One to three times a month         8655 (13.2)           Special occasions only         9630 (14.7)           Never         6186 (9.4)           Smoking status, n (%)         33.0 (1.6)           Categories of age at menarche, n (sd)         13.0 (1.6)           Categories of age at menarche, n (sd)         13.0 (1.6)           Categories of age at menarch	Black	1059 (1.6)
Others         609 (0.9)           Qualifications, n (%)            None of the above         10955 (16.9)           O level or CSEs or other         25619 (39.4)           A level         7626 (11.7)           College/ university         20749 (31.9)           Townsend deprivation index at recruitment, mean (sd)         -1.4 (3.0)           Comparative body size at age 10, n (%)         21749 (31.6)           Average         32767 (50.7)           Thinner         20446 (31.6)           Plumper         11435 (17.7)           Body mass index (BMI), mean (sd)         27.1 (5.2)           Alcohol intake frequency., n (%)         27           Daily or almost daily         10516 (16.0)           Three or four times a week         13712 (20.9)           Once or twice a week         16872 (25.7)           One to three times a month         8655 (13.2)           Special occasions only         9630 (14.7)           Never         38915 (59.5)           Previous         20609 (31.5)           Current         5834 (8.9)           Age when periods started (menarche), mean (sd)         13.0 (1.6)           Categories of age at menarche, n (%)         33076 (45.9)           13.4 Years         2481	Chinese	220 (0.3)
Qualifications, n (%)         10955 (16.9)           None of the above         10955 (16.9)           O level or CSEs or other         25619 (39.4)           A level         7626 (11.7)           College/ university         20749 (31.9)           Townsend deprivation index at recruitment, mean (sd)         -1.4 (3.0)           Comparative body size at age 10, n (%)         -1.4 (3.0)           Average         32767 (50.7)           Thinner         20416 (31.6)           Plumper         11435 (17.7)           Body mass index (BMI), mean (sd)         27.1 (5.2)           Alcohol intake frequency., n (%)         27.1 (5.2)           Daily or almost daily         10516 (16.0)           Three or four times a week         13712 (20.9)           Once or twice a week         16872 (25.7)           One to three times a month         8655 (13.2)           Special occasions only         9630 (14.7)           Never         38915 (59.5)           Previous         206009 (31.5)           Current         5834 (8.9)           Age when periods started (menarche), mean (sd)         13.0 (1.6)           Categories of age at menarche, n (%)         33.0 (16.9)           <13 years	Others	609 (0.9)
None of the above         10955 (16.9)           O level or CSEs or other         25619 (39.4)           A level         7626 (11.7)           College/ university         20749 (31.9)           Townsend deprivation index at recruitment, mean (sd)         -1.4 (3.0)           Comparative body size at age 10, n (%)         32767 (50.7)           Average         32767 (50.7)           Thinner         204416 (31.6)           Plumper         11435 (17.7)           Body mass index (BMI), mean (sd)         27.1 (5.2)           Alcohol intake frequency., n (%)         27.1 (5.2)           Daily or almost daily         10516 (16.0)           Three or four times a week         13712 (20.9)           Once or twice a week         16872 (25.7)           On to three times a month         8655 (13.2)           Special occasions only         9630 (14.7)           Never         6186 (9.4)           Smoking status, n (%)         38915 (59.5)           Previous         20609 (31.5)           Current         5834 (8.9)           Age when periods started (menarche), mean (sd)         13.0 (1.6)           Categories of age at menarche, n (%)         208057 (44.1)           13.14 years         28057 (44.1)           214 </td <td>Qualifications, n (%)</td> <td></td>	Qualifications, n (%)	
O level or CSEs or other         25619 (39.4)           A level         7626 (11.7)           College/ university         20749 (31.9)           Townsend deprivation index at recruitment, mean (sd)         -1.4 (3.0)           Comparative body size at age 10, n (%)	None of the above	10955 (16.9)
A level       7626 (11.7)         College/ university       20749 (31.9)         Townsend deprivation index at recruitment, mean (sd)       -1.4 (3.0)         Comparative body size at age 10, n (%)       32767 (50.7)         Average       32767 (50.7)         Thinner       20416 (31.6)         Plumper       11435 (17.7)         Body mass index (BMI), mean (sd)       27.1 (5.2)         Alcohol intake frequency., n (%)       27.1 (5.2)         Daily or almost daily       10516 (16.0)         Three or four times a week       13712 (20.9)         Once or twice a week       16872 (25.7)         One to three times a month       8655 (13.2)         Special occasions only       9630 (14.7)         Never       6186 (9.4)         Smoking status, n (%)       38915 (59.5)         Previous       20609 (31.5)         Current       5834 (8.9)         Age when periods started (menarche), mean (sd)       13.0 (1.6)         Categories of age at menarche, n (%)       24811 (39.0)         '13 years       24817 (39.0)         '13-14 years       248057 (44.1)         '14       10762 (16.9)         Number of live births, n (%)       12367 (18.9)	O level or CSEs or other	25619 (39.4)
College/ university         20749 (31.9)           Townsend deprivation index at recruitment, mean (sd)         -1.4 (3.0)           Comparative body size at age 10, n (%)         32767 (50.7)           Average         32767 (50.7)           Thinner         20416 (31.6)           Plumper         11435 (17.7)           Body mass index (BMI), mean (sd)         27.1 (5.2)           Alcohol intake frequency., n (%)         20516 (16.0)           Daily or almost daily         10516 (16.0)           Three or four times a week         13712 (20.9)           Once or twice a week         16872 (25.7)           One to three times a month         8655 (13.2)           Special occasions only         9630 (14.7)           Never         6186 (9.4)           Smoking status, n (%)         38915 (59.5)           Previous         20609 (31.5)           Current         5834 (8.9)           Age when periods started (menarche), mean (sd)         13.0 (1.6)           Categories of age at menarche, n (%)         24811 (39.0)           <13 years	A level	7626 (11.7)
Townsend deprivation index at recruitment, mean (sd)       -1.4 (3.0)         Comparative body size at age 10, n (%)       32767 (50.7)         Average       32767 (50.7)         Thinner       20416 (31.6)         Plumper       11435 (17.7)         Body mass index (BMI), mean (sd)       27.1 (5.2)         Alcohol intake frequency., n (%)       0         Daily or almost daily       10516 (16.0)         Three or four times a week       13712 (20.9)         Once or twice a week       16872 (25.7)         One to three times a month       8655 (13.2)         Special occasions only       9630 (14.7)         Never       6186 (9.4)         Smoking status, n (%)       20609 (31.5)         Current       5834 (8.9)         Age when periods started (menarche), mean (sd)       13.0 (1.6)         Categories of age at menarche, n (%)       13.0 (1.6)         13.14 years       28057 (44.1)         >14       10762 (16.9)         Number of live births, n (%)       12367 (18.9)	College/ university	20749 (31.9)
Comparative body size at age 10, n (%)         32767 (50.7)           Average         32767 (50.7)           Thinner         20416 (31.6)           Plumper         11435 (17.7)           Body mass index (BMI), mean (sd)         27.1 (5.2)           Alcohol intake frequency., n (%)         20           Daily or almost daily         10516 (16.0)           Three or four times a week         13712 (20.9)           Once or twice a week         16872 (25.7)           One to three times a month         8655 (13.2)           Special occasions only         9630 (14.7)           Never         6186 (9.4)           Smoking status, n (%)         20009 (31.5)           Current         5834 (8.9)           Age when periods started (menarche), mean (sd)         13.0 (1.6)           Categories of age at menarche, n (%)         13.0 (1.6)           Categories of age at menarche, n (%)         24811 (39.0)           13-14 years         24811 (39.0)           >14         10762 (16.9)           Number of live births, n (%)         0           0         12367 (18.9)	Townsend deprivation index at recruitment, mean (sd)	-1.4 (3.0)
Average         32767 (50.7)           Thinner         20416 (31.6)           Plumper         11435 (17.7)           Body mass index (BMI), mean (sd)         27.1 (5.2)           Alcohol intake frequency., n (%)         27.1 (5.2)           Daily or almost daily         10516 (16.0)           Three or four times a week         13712 (20.9)           Once or twice a week         16872 (25.7)           One to three times a month         8655 (13.2)           Special occasions only         9630 (14.7)           Never         6186 (9.4)           Smoking status, n (%)         20609 (31.5)           Current         5834 (8.9)           Age when periods started (menarche), mean (sd)         13.0 (1.6)           Categories of age at menarche, n (%)         13.0 (1.6)           <13 years	Comparative body size at age 10, n (%)	
Thinner       20416 (31.6)         Plumper       11435 (17.7)         Body mass index (BMI), mean (sd)       27.1 (5.2)         Alcohol intake frequency., n (%)       10516 (16.0)         Daily or almost daily       10516 (16.0)         Three or four times a week       13712 (20.9)         Once or twice a week       16872 (25.7)         One to three times a month       8655 (13.2)         Special occasions only       9630 (14.7)         Never       6186 (9.4)         Smoking status, n (%)       1         Never       38915 (59.5)         Previous       20609 (31.5)         Current       5834 (8.9)         Age when periods started (menarche), mean (sd)       13.0 (1.6)         Categories of age at menarche, n (%)       13.0 (1.6)         Categories of age at menarche, n (%)       28057 (44.1)         >14       10762 (16.9)         Number of live births, n (%)       0       12367 (18.9)	Average	32767 (50.7)
Plumper       11435 (17.7)         Body mass index (BMI), mean (sd)       27.1 (5.2)         Alcohol intake frequency., n (%)       10516 (16.0)         Daily or almost daily       10516 (16.0)         Three or four times a week       13712 (20.9)         Once or twice a week       16872 (25.7)         One to three times a month       8655 (13.2)         Special occasions only       9630 (14.7)         Never       6186 (9.4)         Smoking status, n (%)       13000 (31.5)         Current       38915 (59.5)         Previous       20609 (31.5)         Current       5834 (8.9)         Age when periods started (menarche), mean (sd)       13.0 (1.6)         Categories of age at menarche, n (%)       13.0 (1.6)         Categories of age at menarche, n (%)       24811 (39.0)         13-14 years       28057 (44.1)         >14       10762 (16.9)         Number of live births, n (%)       0         0       12367 (18.9)	Thinner	20416 (31.6)
Body mass index (BMI), mean (sd)       27.1 (5.2)         Alcohol intake frequency., n (%)       10516 (16.0)         Daily or almost daily       10516 (16.0)         Three or four times a week       13712 (20.9)         Once or twice a week       16872 (25.7)         One to three times a month       8655 (13.2)         Special occasions only       9630 (14.7)         Never       6186 (9.4)         Smoking status, n (%)       1         Never       38915 (59.5)         Previous       20609 (31.5)         Current       5834 (8.9)         Age when periods started (menarche), mean (sd)       13.0 (1.6)         Categories of age at menarche, n (%)       13.0 (1.6)         13 years       24811 (39.0)         13-14 years       28057 (44.1)         >14       10762 (16.9)         Number of live births, n (%)       0         0       12367 (18.9)	Plumper	11435 (17.7)
Alcohol intake frequency., n (%)       10516 (16.0)         Daily or almost daily       10516 (16.0)         Three or four times a week       13712 (20.9)         Once or twice a week       16872 (25.7)         One to three times a month       8655 (13.2)         Special occasions only       9630 (14.7)         Never       6186 (9.4)         Smoking status, n (%)       V         Never       38915 (59.5)         Previous       20609 (31.5)         Current       5834 (8.9)         Age when periods started (menarche), mean (sd)       13.0 (1.6)         Categories of age at menarche, n (%)       24811 (39.0)         13-14 years       24811 (39.0)         14       10762 (16.9)         Number of live births, n (%)       U         0       12367 (18.9)	Body mass index (BMI), mean (sd)	27.1 (5.2)
Daily or almost daily       10516 (16.0)         Three or four times a week       13712 (20.9)         Once or twice a week       16872 (25.7)         One to three times a month       8655 (13.2)         Special occasions only       9630 (14.7)         Never       6186 (9.4)         Smoking status, n (%)          Never       38915 (59.5)         Previous       20609 (31.5)         Current       5834 (8.9)         Age when periods started (menarche), mean (sd)       13.0 (1.6)         Categories of age at menarche, n (%)       24811 (39.0)         13-14 years       28057 (44.1)         >14       10762 (16.9)         Number of live births, n (%)       0       12367 (18.9)	Alcohol intake frequency., n (%)	
Three or four times a week       13712 (20.9)         Once or twice a week       16872 (25.7)         One to three times a month       8655 (13.2)         Special occasions only       9630 (14.7)         Never       6186 (9.4)         Smoking status, n (%)          Never       38915 (59.5)         Previous       20609 (31.5)         Current       5834 (8.9)         Age when periods started (menarche), mean (sd)       13.0 (1.6)         Categories of age at menarche, n (%)       13.0 (1.6)         Categories of age at menarche, n (%)       28057 (44.1)         >14       10762 (16.9)         Number of live births, n (%)       0       12367 (18.9)	Daily or almost daily	10516 (16.0)
Once or twice a week         16872 (25.7)           One to three times a month         8655 (13.2)           Special occasions only         9630 (14.7)           Never         6186 (9.4)           Smoking status, n (%)            Never         38915 (59.5)           Previous         20609 (31.5)           Current         5834 (8.9)           Age when periods started (menarche), mean (sd)         13.0 (1.6)           Categories of age at menarche, n (%)         13.0 (1.6)           13 years         24811 (39.0)           13-14 years         28057 (44.1)           >14         10762 (16.9)           Number of live births, n (%)         12367 (18.9)	Three or four times a week	13712 (20.9)
One to three times a month         8655 (13.2)           Special occasions only         9630 (14.7)           Never         6186 (9.4)           Smoking status, n (%)         38915 (59.5)           Previous         20609 (31.5)           Current         5834 (8.9)           Age when periods started (menarche), mean (sd)         13.0 (1.6)           Categories of age at menarche, n (%)         13.0 (1.6)           13 years         24811 (39.0)           13-14 years         28057 (44.1)           >14         10762 (16.9)           Number of live births, n (%)         12367 (18.9)	Once or twice a week	16872 (25.7)
Special occasions only         9630 (14.7)           Never         6186 (9.4)           Smoking status, n (%)            Never         38915 (59.5)           Previous         20609 (31.5)           Current         5834 (8.9)           Age when periods started (menarche), mean (sd)         13.0 (1.6)           Categories of age at menarche, n (%)         24811 (39.0)           13-14 years         28057 (44.1)           >14         10762 (16.9)           Number of live births, n (%)         0         12367 (18.9)	One to three times a month	8655 (13.2)
Never       6186 (9.4)         Smoking status, n (%)       38915 (59.5)         Never       38915 (59.5)         Previous       20609 (31.5)         Current       5834 (8.9)         Age when periods started (menarche), mean (sd)       13.0 (1.6)         Categories of age at menarche, n (%)       13.0 (1.6)         <13 years	Special occasions only	9630 (14.7)
Smoking status, n (%)       38915 (59.5)         Never       38915 (59.5)         Previous       20609 (31.5)         Current       5834 (8.9)         Age when periods started (menarche), mean (sd)       13.0 (1.6)         Categories of age at menarche, n (%)       13.0 (1.6)         <13 years	Never	6186 (9.4)
Never         38915 (59.5)           Previous         20609 (31.5)           Current         5834 (8.9)           Age when periods started (menarche), mean (sd)         13.0 (1.6)           Categories of age at menarche, n (%)         24811 (39.0)           <13 years	Smoking status, n (%)	
Previous       20609 (31.5)         Current       5834 (8.9)         Age when periods started (menarche), mean (sd)       13.0 (1.6)         Categories of age at menarche, n (%)       24811 (39.0)         <13 years	Never	38915 (59.5)
Current       5834 (8.9)         Age when periods started (menarche), mean (sd)       13.0 (1.6)         Categories of age at menarche, n (%)       24811 (39.0)         <13 years	Previous	20609 (31.5)
Age when periods started (menarche), mean (sd)       13.0 (1.6)         Categories of age at menarche, n (%)       24811 (39.0)         <13 years	Current	5834 (8.9)
Categories of age at menarche, n (%)       24811 (39.0)         <13 years	Age when periods started (menarche), mean (sd)	13.0 (1.6)
<13 years	Categories of age at menarche, n (%)	
13-14 years       28057 (44.1)         >14       10762 (16.9)         Number of live births, n (%)       12367 (18.9)	<13 years	24811 (39.0)
>14 10762 (16.9) Number of live births, n (%) 0 12367 (18.9)	13-14 years	28057 (44.1)
Number of live births, n (%) 0 12367 (18.9)	>14	10762 (16.9)
0 12367 (18.9)	Number of live births, n (%)	
	0	12367 (18.9)

medRxiv preprint doi: https://doi.org/10.1101/2022.04.17.22273947; this version posted May 5, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.	
1	8900 (13.6)
2	28526 (43.5)
3+	15767 (24.0)
Had menopause, n (%)	
Premenopausal	15418 (24.5)
Postmenopausal	37248 (59.1)
Surgical	7564 (12.0)
Other	2758 (4.4)
Age at menopause (last menstrual period), mean (sd)	49.7 (5.1)
Categories of age at menopause, n (%)	
<40	1520 (4.1)
40-44	3378 (9.1)
45-49	8903 (23.9)
50-51	8740 (23.4)
52-54	9144 (24.5)
55+	5606 (15.0)
Statin use - Nurses int., n (%)	
No Statins	58279 (88.7)
Statins	7420 (11.3)
Ever used hormone-replacement therapy (HRT), n (%)	
No	40330 (61.7)
Yes	25036 (38.3)
Years on HRT, n (%)	
Never	40330 (64.8)
0-2	6294 (10.1)
3-6	5504 (8.8)
7-10	5192 (8.3)
>10	4908 (7.9)

\*Age at natural menopause therefore excluded women who had not yet gone through the menopause or who had a surgical menopause or who answered 'other'.

# Summary box

#### What is new?

- Markers of women's reproductive health are associated with several common chronic conditions. Whilst some attempts have been made to explore the extent to which these associations are causal, metabolites could act as mediators of the relationship between reproductive markers and chronic diseases.
- Older age of menarche was related to a less atherogenic metabolic profile in multivariable regression and Mendelian randomization, however, this was largely attenuated when accounting for adult body mass index.
- In multivariable regression, higher parity related to complex changes in lipoprotein-related traits. Whilst these were not observed in male negative controls, suggesting a potential causal effect in females, they were not replicated in the Mendelian randomization, possibly due to imprecise estimates.
- Older age at natural menopause was related to lower concentrations of inflammation markers in both multivariable regression and Mendelian randomization. Consistent results were observed for LDLrelated traits when stratified by chronological age.

# Implications

- Given that the age at menarche results were largely attenuated to the null when accounting for adult BMI, it is likely that age at menarche itself may not causally relate to the metabolic profile.
- These results, particularly for parity and age at menopause, could contribute to identifying novel
  markers for the prevention of adverse cardiometabolic outcomes in women and/or methods for
  accurate risk prediction. For example, consistent with other studies, higher parity was associated
  with unfavourable (e.g. higher number of particles and lipid content in VLDL and higher glycine)
  changes in the metabolic profile. Similarly, older age at menopause was related to higher lipid
  content in HDL particles and lower systemic inflammation, as proxied by GlycA.